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Post-transcriptional gene silencing (PTGS) agents such as ribozymes, RNAi and antisense have substantial potential for gene
therapy of human retinal degenerations. These technologies are used to knockdown a speciﬁc target RNA and its cognate protein.
The disease target mRNA may be a mutant mRNA causing an autosomal dominant retinal degeneration or a normal mRNA that
is overexpressed in certain diseases. All PTGS technologies depend upon the initial critical annealing event of the PTGS ligand to
the target RNA. This event requires that the PTGS agent is in a conformational state able to support hybridization and that the
target have a large and accessible single-stranded platform to allow rapid annealing, although such platforms are rare. We address
the biocomplexity that currently limits PTGS therapeutic development with particular emphasis on biophysical variables that
inﬂuence cellular performance. We address the diﬀerent strategies that can be used for development of PTGS agents intended for
therapeutic translation. These issues apply generally to the development of PTGS agents for retinal, ocular, or systemic diseases.
This review should assist the interested reader to rapidly appreciate critical variables in PTGS development and facilitate initial
design and testing of such agents against new targets of clinical interest.
1.PTGSTechnologies
The basic mechanisms of antisense (AS), ribozyme (Rz),
and RNA interference (RNAi) approaches to PTGS will be
presented here. A comparison of their properties is presented
(Table 1).
1.1. Antisense. AS intended for clinical use is an oligodeoxy-
nucleotide (ODN) string with bases chosen to form Watson
Crick annealing pairs over an accessible region of the target
mRNA or viral RNA. Various backbone formulations have
been used with the intent of resisting nuclease degradation
outside or inside cells, enhancing, the binding energy to the
target RNA, reducing the strong electrostatic repulsive ener-
gies during annealing, and enhancing speciﬁcity of RNase H
attack. Modiﬁcations to the intrinsic phosphodiester back-
bone chemistry include: phosphorothioate, methylphospho-
noester, peptide nucleic acid, 2-ortho-methyl-deoxyribose,
locked nucleic acid, and morpholino. Chemical modiﬁca-
tions inﬂuence cellular uptake, and AS ODNs are provided
to tissues directly rather than being expressed within cells
from a genetic construct. Chemical modiﬁcations of ODNs
and such engineered properties are not the focus here,
and an interested reader should consult prior literature [1–
4]. Single-stranded ODNs are transfected or transduced
into cells where they diﬀuse and encounter target RNAs
in either the nucleus or cytoplasm. Two generally accepted2 Journal of Ophthalmology
Table 1: Comparison of the properties of antisense, ribozyme, and RNAi.
Property Antisense Ribozyme siRNA/shRNA/miRNA
Size Small (15–20nt) Small (42–60nt) Small (19–22nt)∗
Crystal structure No Yes Yes (RISC)
Mechanism of action Known Known Known
Independence cell metabolism No Yes No
Speciﬁcity Moderate High Poor to moderate
Saturable No No Yes
Cellular compartment Cytoplasm Nucleus/cytoplasm Cytoplasm
Dependence on target structure Yes Yes Yes
Proven in vivo Yes Yes Yes
∗On one strand engaged in the RISC complex after cellular processing.
+
AS ODN
Target
RNase H
Figure 1: Antisense mechanism. A schematic representation is
shown for two dominant mechanisms by which AS ODN molecules
deliveredintocellscansuppressgeneexpression.TheASODNmust
ﬁrstannealtoanaccessibleregionofthetargetmRNA.Theﬁrstand
likely dominant mechanism of inhibition is through recruitment
of RNaseH (green) to cleave the RNA is the center of the ODN:
TargetRNAhybridregion.Thesecondmechanisminvolvesphysical
hindrance of biochemical processes operative on the mRNA such
as ribosome- (violet-) mediated translation, 5  decapping, and 3 
deadenylation. Here, the hybridized ODN is depicted blocking the
progress of translating ribosomes on the mRNA.
mechanisms of AS ODN inhibition of gene expression are
both dependent upon strong annealing to the target RNA
(Figure 1). These include ODN catalysis of target RNA
degradation by RNaseH and/or physical blockade mech-
anisms (e.g., translation block through ribosome stalling,
blocking splicing, blocking polyadenylation) [1, 2, 4, 5].
The ﬁrst mechanism can occur anywhere in the processed
RNA, whereas the second mechanism must occur within
the coding region of the target or at sites of splicing
or polyadenylation. The translating ribosome can remove
antisense ODNs due to its helicase function [6]. There-
fore, AS conformational block may best be conducted at
or in proximity of the translation initiation codon. AS
inhibition of target gene expression can, therefore, occur
at the post-transcriptional or cotranslational levels. The
RNaseH-mediated mechanism of inhibition can occur with
phosphodiesterorphosphorothioatebackbonesoftheODN.
The upstream cleavage product by RNaseH has a 3  hydroxyl
and the downstream cleavage product has a 5  phosphate.
Information has accumulated that the RNaseH mechanism
lacks great speciﬁcity with fully cleavable ODNs in that
only a small number (≤5nt) of annealing nucleotides (nt)
are suﬃcient to support target phosphodiester cleavage [7,
8]. This results in substantial oﬀ-target eﬀects and has
sponsored the development of second-generation agentsthat
have modiﬁed backbone and sugar chemistries. Many of
these chemistries act to increase the aﬃnity of the ODN
to the target RNA. On the other hand, they do not allow
RNaseH-mediated cleavage. In pure form, such agents may
not have high eﬃcacy when transduced into mammalian
cells, indicating that the physical blockade mechanisms are
not the most potent. Second-generation chimeric antisense
molecules were then engineered that contained the modiﬁed
chemistries for the backbones and sugars but also a central
core of deoxynucleotides that permit RNaseH cleavage. Such
chimeras have increased potency on the basis of catalyzing
RNaseH attack on a target and speciﬁcity because of the
strength of binding to the target [7, 9, 10]. During early
development, RNaseH activity appeared to be the dominant
mechanism of AS inhibition [11]. More recently, a combi-
nation of mechanisms is thought to be embraced depending
upon the chemical nature of the ODN [12]. An eﬀective
AS PTGS agent requires an accessible region in the target
RNA and especially strong binding energy of the ODN to
the target RNA. The lifetime of the bound ODN: target state
must be suﬃciently long to embrace the natural kinetics of
RNaseHanditsstoichiometry-dependentkineticsormustbe
suﬃciently long to impair translation of substantial numbers
ofcognateprotein molecules.TheASreactionschemecanbe
simply represented as follows:
ODN+RNA
k1

k−1
ODN : RNA. (1)
The dissociation constant (Kd)i sg i v e nb y
Kd =
[ODN][RNA]
[ODN : RNA]
=
k−1
k1
. (2)
For AS, Rz, and RNAi,o nr a t e s( k1) of interaction between
the PTGS agent and the target mRNA are limited by the
expected rate of forming a nucleic acid double-stranded
helix in solution from two (idealized) random coils (esti-
mated at 5 × 107 M−1 min−1), with the assumption ofJournal of Ophthalmology 3
preexisting regions of single-stranded accessibility able to
support immediate base pairing [13]. However, measured
AS annealing rates vary more than dissociation rates and
appear responsible for the profound range of Kd values
that span several orders of magnitude against a single-target
mRNA [14–16]. The fact that the ON rates have such a
wide variation is likely an index of the varying landscape
of accessibility at diﬀerent regions in a folded target mRNA
or potential inaccessibility in the structure of the AS ligand
that limits annealing (e.g., [15, 17–19]). OFF rates (k−1)a r e
typically many orders of magnitude smaller than on rates
suchthatKd canbeapproximatedbythesimpleratioofrates.
The net energetic eﬀects of the AS-binding process reﬂect
the losses of potential inhibitory secondary structures in the
target or AS ligand and the gain achieved by the annealing
event. The strength of binding or the free energy (ΔG) of the
AS dissociation reaction is represented as
ΔG =− RT lnKd. (3)
ΔGataparticulartemperaturecanbecalculatedfromnearest
neighbor tabulations of ΔH and ΔS [20, 21]. ΔG can then be
used to calculate Kd from which k−1 (dissociation rate) can
be calculated. k−1 can then be used to calculate the lifetime
(time constant) of the AS bound state
τ−1 =
ln2
k−1
=
0.693
k−1
. (4)
Assume the lifetime of a cellular mRNA target that codes
f o rar e l a t i v e l ya b u n d a n tp r o t e i ni s1 0h o u r s .I no r d e rt o
manifest signiﬁcant target knockdown, an AS agent must
remain stably bound to the target mRNA for a period at
least as long as the target mRNA lifetime. The lifetime of
the target: ODN complex allows RNaseH-mediated cleavage
of the target mRNA or translation arrest. For an mRNA
with a mean 10hr lifetime, k−1 should be on the order of
1.2 × 10
−3 min−1,a n dKd would be 23.1 picoMolar. AS-
binding aﬃnities can vary over several log orders depending
upon the target sequence and are often not as strong as
23pM [14–16, 22, 23]. The dominant factor in achieving a
successful agent is to ﬁrst identify the regions in the target
mRNA that are indeed accessible to annealing (see [18, 19]).
The length of the ODN and the backbone chemistry should
be chosen appropriately to achieve a suﬃcientlynegativeΔG,
which can be calculated from nearest neighbor frequencies.
Web databases for AS ODN eﬀectiveness studies are available
[24–26]. The in vitro binding capacity and aﬃnity of AS
agentstotargetmRNAsappearstocorrelatewithknockdown
potential in live cells [18, 19]. That local target accessibility
is a major limiting variable in vivo has been shown by
engineering a single AS annealing site into a reporter target
mRNA in diﬀerent local structural contexts and then testing
knockdown by a single AS ODN relative to control [27].
There was marked changes in knockdown by the single
AS ODN when its target sequence was present in diﬀerent
secondary structural contexts.
Vitrovene (fomiversen, Isis-2922) (Novartis, ISIS), cur-
rently the only FDA approved (August 1998) PTGS agent
(antisense) for human use (CMV retinitis), is a 21-mer
phosphorothioate AS ODN that anneals to the coding region
of the mRNA transcribed from the major immediate-early
(IE55) gene of the CMV genome [28–30].
1.2. Ribozymes. General reviews on the ribozyme are avail-
able [31–38]. A ribozyme is a catalytic RNA. The chemistry
of RNA is suﬃciently robust that it can fold into structures
that permit speciﬁc phosphodiester bond cleavage in other
target RNAs. There are several forms of ribozyme that have
been identiﬁed. We focus on the hammerhead ribozyme
(hhRz), because it has the most versatile set of cleavage sites
(NUH↓, where N = G, C, U, A; H = C, U, A), because a
largeknowledgebaseisestablishedforthisRNAenzyme,and
because the internal equilibrium of the reaction is strongly
biased toward cleavage (k2) as opposed to religation (k−2)
(>100:1). The hairpin ribozyme (hpRz) recognizes a broad
set of target motifs, but has a religation rate that exceeds
cleavage rate (10:1) such that religation is favored over
cleavage [39, 40]. These issues complicate its potential for
therapeutics, because there are fewer places to cleave a tightly
compact target and cleaved target products can be relgated
by the same agent unless they are displaced rapidly. For the
hhRz there are an average of one NUH↓ cleavage site every
twelve nts (1/4 × 1/1 × 1/3 = 1/12). Therefore, even an
average size mRNA has a rich abundance of potential NUH↓
cleavage sites. This increases the probability for having a
potential cleavage site in a rare region of target accessibility.
Diﬀerent NUH↓ cleavage sites demonstrate variation in the
rate of cleavage with the two naturally occurring motifs
(GUC↓,G U A ↓) having the greatest intrinsic cleavage rates
[41–44]. In addition to the NUH↓ cleavage motif hhRzs can
be designed to cleave at NHH↓, but the catalytic rates are
substantially reduced compared to high level GUC↓ motif
[32]. All hhRzs cleave a phosphodiester bond to leave an
upstream product terminated at the 3  end with a cyclic 2 3 
phosphate and a downstream product terminated at the 5 
end with a hydroxyl group. Once the target mRNA is cleaved
by the hhRz, the fragments are more readily degraded by
exonucleases in the cell because of the loss of the polyadeny-
lation signal at the 3  end of the upstream fragment and the
loss of the cap on the 5  end of the downstream fragment.
A simplistic reaction schematic for the hhRz is shown
(Figure 2). The hhRz folds into a conformation which is
stabilized by Stem II. In its trans format, which is used for
gene therapeutic purposes, the two antisense ﬂanks form
S t e m sI( 5   AS ﬂank) and III (3  AS ﬂank) upon annealing to
the target RNA. Annealing sets the stage for conformational
changes (Rz
 ) that prepare and align the enzyme core with
the phosphodiester bond at the target cleavage site. The Hnt
of the NUH↓ cleavage motif does not hydrogen bond to
the hhRz. Upon cleavage the two products (P1, P2) must
dissociate from the AS arms of the hhRz in order to free
the hhRz to anneal to another target RNA and promote true
catalytic turnover of substrate:
Rz+RN A
k1

k−1
Rz : RNA
kES

k−ES
Rz
  :R N A
k2

k−2
Rz : P1 ·P2  Rz+P1+P2
(5)4 Journal of Ophthalmology
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Figure 2: Ribozyme mechanism. A schematic reperesentation is shown with a simpliﬁed accessible region in a target mRNA with a cleavable
hhRz NUH↓ motif, (GUC↓). The hhRz, drawn in an open enzymatically patent state, binds to the accessible target region by Watson Crick
base pairing. Annealing precisely aligns the phosphodiester bond of the H residue (C here) with the enzymatic core of the catalytic RNA.
The annealing reaction has an equilibrium speciﬁed by the ratio of rates k1 and k−1.C h e m i c a lc l e a v a g e( k2) occurs to yield two products
which remain bound to the AS ﬂanks of the hhRz. Each product leaves with its own characteristic equilibrium determined by the strength
of binding to the hhRz AS ﬂanks. Product dissociation permits the enzyme to collide with another substrate and initiate subsequent rounds
of catalysis as a Michaelis-Menten enzyme to achieve catalytic target turnover characterized by kcat/Km.
As for AS, the initial dissociation constant (Kd)i sg i v e nb y
Kd =
[hhRz][RNA]
[hhRz] : [RNA]
=
k−1
k1
. (6)
Like AS, Rz and RNAi have ON rates (k1) that are typically
limited by the expected diﬀusion-limited rate of forming
a nucleic acid double-stranded helix in solution from two
(idealized) random coils (estimated at 5 × 107 M−1min−1).
Again, association rates are typically orders of magnitude
lower than this index. OFF rates (k−1) are typically many
orders of magnitude smaller than ON rates such that Kd
can be approximated by the simple ratio of rates. The free
energy of the Rz dissociation reaction is represented as in (3)
above. ΔG at a particular temperature can be calculated from
nearest neighbor tabulations of ΔH and ΔS [20, 21]. ΔG can
then be used to calculate Kd from which k−1 (dissociation
rate) can be calculated. k−1 can then be used to calculate the
lifetime(timeconstant)oftheRzboundstateasin(4)abo v e.
The total AS ﬂank lengths (Stem I + Stem III, H does not
hydrogen bond) of the Rz should be no more than 12–16nts,
depending upon the sequence context, in order to achieve a
full annealing energy of between −12 to −16kCal/mole [45].
HhRzsthatbindtootightlytotargetRNAwillhaveslowOFF
rates prior to chemical cleavage (rate limiting for the ideal
hhRz performance). Slow initial OFF rates could result in a
loss of speciﬁcity for the intended target because chemical
cleavage could occur if an NUH↓ site of an unintended target
happened to be centrally placed within the AS ﬂank span.
The likelihood that an unintended target could precisely
position itself on a given hhRz for cleavage at an NUH↓
site is, in fact, low, unless the unintended target had almost
precise sequence identity to the intended target. This factor
has been presented as a factor for hhRz speciﬁcity [46]. In
addition, hhRz catalytic function is intolerant to base-pair
mismatches near the core of the enzyme [47], which would
act to decrease cleavage of bound nontarget mRNAs that do
not have precise sequence speciﬁcity for annealing; in fact,
this attribute of the hhRz can be used as a component ofJournal of Ophthalmology 5
a therapeutic strategy to suppress mutated versus normal
target mRNAs in hereditary diseases (see below). Oﬀ-target
eﬀects with a hhRz would more likely result from pure AS
eﬀects independent of catalytic chemical cleavage. With an
optimum total antisense ﬂank length for catalysis on the
order of 12–16nt, the stable annealing of unintended targets
with mismatches relative to the hhRz is expected to occur
with low probability. The expected speciﬁcity of the hhRz is
a considerable distinction from the mismatch tolerant AS or
RNAi processes.
Another challenge with the hhRz is the issue of product
inhibition. If the two products cannot melt oﬀ of the
antisense ﬂanks of the hhRz after cleavage at physiological
temperature, or one product is delayed in leaving, then
the hhRz will be trapped in association with cleaved target
and unable to recognize and anneal to subsequent target
RNA molecules. This problem impacts catalytic turnover
or enzyme eﬃciency (kcat/Km). A kinetic model exists for
the hhRz that can greatly assist in the design of antisense
ﬂanks that permit energies of annealing suﬃcient to allow
the hhRz to bind long enough to permit chemical cleavage
(∼ =1/min) but not too long to promote product inhibition
[13]. It is important to determine the extent to which target
knockdown by a hhRz is due to catalytic, antisense, or
catalytic antisense eﬀects. There are several mutations that
can be made at key residues in the enzymatic core of the
hhRz, which are known to completely obviate catalysis (e.g.,
G5C, G8C, G12C [41, 44, 48]). Comparing the level of target
knock down (RNA or protein or both) by a fully catalytic
hhRz compared to a mutated hhRz should allow suﬃcient
information to determine the extent to which the hhRz is
performing catalytically, which is the desired outcome. A
hhRz with truecatalytic performance in vivo canknockdown
signiﬁcantly more target molecules in a given epoch of time
than a hhRz that does not have this capacity (e.g., pure AS
eﬀect without cleavage or a catalytic antisense eﬀect with
annealingandcleavagebutnoproductreleaseandturnover).
Hence, hhRzs that demonstrate catalytic turnover in live
human cells require lower expression levels to achieve the
same levels of target knockdown than those that do not have
Michaelis-Menten turnover potential. Lower levels of PTGS
agent expression are expected to decrease the potential for
cellular toxicity and oﬀ target eﬀects.
A relatively stable mRNA is a good target for gene
silencing, because hhRzs are relatively slow enzymes. The
intrinsic cleavage rate is maximal against small unstruc-
tured substrate RNAs and on the order of 1/min, which
is several orders of magnitude slower than proteinaceous
enzymes. Structured targets typically have slower cleavage
rates. Because of the slow speed of catalytic RNAs, the
intrinsic degradation kinetics of the target RNA (without
the hhRz) and with the hhRz RNA must be considered. It
is important to consider the lifetime of the target mRNA
in its dominant locale within the cell. Targets that have
short lifetimes (e.g., pulse transcribed mRNA with rapid
turnover such a cell-cycle control genes) may be diﬃcult to
attack with current hhRzs, because the targets intrinsically
degrade at a rate that cannot be practically impacted by a
hhRz. One will want to choose targets carefully to insure that
there is suﬃcient time for enzymatic turnover within the cell
at expression levels of the PTGS agent that are not toxic.
We would recommend target mRNAs that have lifetimes
on the order of several hours. Fortunately, most autosomal
dominant disease genes and normal genes transcribe fairly
stable mRNAs as potentially validated targets for PTGS
therapeutics.Thesetypicallycodeforsignaling,structural,or
enzymatic proteins in photoreceptors and RPE cells. Any Rz
acts kinetically by providing an additional component to the
intrinsic degradation rate for a target RNA. The total rate of
degradation of the target mRNA is the sum of the intrinsic
and Rz-induced degradation rates (kcat = kint + kPTGS).
Clearly, if the intrinsic degradation rate is much faster than
the rate of intracellular Rz catalysis, then kcat ∼ = kint,a n d
there can be no signiﬁcant knockdown of target RNA and
protein mediated by the PTGS agent. An hhRz or an RNAi
can be most eﬀective if kPTGS   kint. On face value, this
substantiallyrestrictsthetypesofmRNAsthatcanbesuitable
targets. RNAs with very short half-lives, such as those coding
for transiently induced transcription factors, are unlikely
to be viable targets because kPTGS ≈ kint or kPTGS <k int.
Therefore, before embarking on the development of a PTGS
agent for a particular target, it is prudent to have knowledge
regarding the intrinsic degradation half life of the target
mRNA in the cells in which gene therapy would need to be
administered.
A ribozyme designed to cleave the mRNA for proliferat-
ing cell nuclear antigen [49] was recently tested in a Phase I
clinical trial for proliferative vitreoretinopathy [50].
1.3. RNAi Technology. Recent reviews will serve to orient
the unfamiliar reader [51–53]. RNAi refers to an evolution-
arily conserved phenomenon where double-stranded RNA
(dsRNA) mediates the sequence-speciﬁc cleavage of target
RNA using cellular machinery (Figure 3). In mammalian
cells, RNAi is triggered by 21–23nt RNA duplexes with
symmetric 2nt 3  overhangs and 5 -phosphate termini
called small interfering RNA (siRNA) [54–56]. These siRNA
duplexes are processed from longer dsRNA by the ribonucle-
ase III enzyme Dicer [57]. Dicer processed siRNA duplexes
associate with a multiprotein complex known as the RNA-
inducing silencing complex (RISC), and one strand of
the duplex is loaded into RISC to serve as the AS guide
strand. Within RISC, the guide RNA strand is bound by the
Argonaute 2 protein that contains an amino-terminal Piwi
Argonaute Zwille (PAZ) domain and a carboxy-terminal
PIWI domain containing the catalytic RNA slicer site [58].
The PAZ domain recognizes and anchors the 3  overhang of
the duplex [59–61] while the PIWI domain anchors the 5 
end of the guide RNA [62]. The guide strand then adopts
a A-form helix that extends along a channel in the PIWI
domain, aligning the scissile phosphate of the target strand
with the slicer catalytic site one helical turn away from the 5 
anchored end [63]. The PIWI domain is similar in structure
to RNaseH. After RISC cleavage, the upstream product has a
3  hydroxyl and the downstream product has a 5  phosphate.
Despite the association of a cellular protein complex,
eﬀective gene silencing is still not realized with many siRNA
or expressed short hairpin (shRNA) sequences [64]. Three6 Journal of Ophthalmology
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Figure 3: RNAi mechanism. An expressed RNA hairpin (shRNA) is cleaved ﬁrst by Dicer III to a double-stranded RNA of 21nt with 5 
phosphorylated ends. A pri-miRNA is processed in the nucleus into a pre-miRNA by Drosha, leaves the nucleus, and is further processed
by Dicer in the cytoplasm or as part of RISC. Or a transfected or transduced siRNA is phosphorylated at each 5  end. The short dsRNAs
are incorporated into the RISC complex, and the antisense strand (guide strand) is selected on the basis of engineering weaker 5  energy
than 3  energy. The passenger strand is displaced. The guide strand is organized into RISC as an A-form α-helix within Ago2, which is
the RNA endonuclease of RISC. By diﬀusion limitations, loaded RISC searches for a complimentary partner to its antisense element in the
transcriptosome. Upon collision, kissing complex formation and full annealing, the target RNA is positioned for endonuclease cleavage by
Ago2. After cleavage, it is thought that ATP hydrolysis occurs, which provides helicase energy to strip the products from the Ago2 cavity in
ordertopreventproductinhibitiononRNAi.ProductreleasethenfreesthechargedRISCtoseekothertargetmRNAsforsubsequentrounds
of Michaelis-Menten turnover.
crucial kinetic parameters are strongly implicated in the
ability of a given siRNA sequence to eﬀectively promote
gene silencing in physiological conditions: the loading of
the correct antisense RNA guide strand into RISC, target
mRNAsiteannealing,andRISCreloading.Theseparameters
are aﬀected by sequence-speciﬁc problems. For the ﬁrst
parameter, loading of RISC, the thermodynamic stability of
the RNA ends has been shown to be the major determinant
of which strand of the siRNA duplex is incorporated into
RISC. Theoretically, either strand of the siRNA duplex can
be incorporated into RISC, but only one strand will be
AS for a given sense mRNA target. The discovery that the
strand with the greater thermodynamic instability in the
5  end is preferentially loaded into RISC has improvedJournal of Ophthalmology 7
the design of successful siRNAs or shRNAs [65, 66]b y
allowing the preferential loading of the correct antisense
guide strand. While the loading of RNA guide strands
into RISC is an RNAi-speciﬁc problem, the problem of
the limits of target mRNA site accessibility and annealing
that occurs for AS and ribozyme PTGS agents also aﬀects
eﬃcacy of siRNA sequences [67–74]. Fundamentally, the
Watson-crick base pairing that is required for all of these
technologies profoundly limits the number of target mRNA
regionsthatwillsupporteﬀectivegenesilencing.LikeASand
ribozymes,targetrecognitionforRNAialsoseemstoproceed
by diﬀusion [71], with the guide strand of the RISC complex
encountering sites nonspeciﬁcally until proper annealing
with the target site forms the necessary geometry for RISC
cleavage. Target recognition is dominated by the 5  region
of siRNA, which nucleates binding of target RNA with RISC
and contributes to the overall strength of binding between
the target RNA and RISC. The 5  region of the siRNA (2–
8nt) has been called the “seed” sequence. The annealing
of the central and 3  regions are important for establishing
the A-form helical geometry that is needed for eﬃcient
central cleavage [75, 76]. Although RISC proceeds with
greatest activity when it anneals to a fully complementary
target, it can still cleave RNA targets with mismatched bases,
especially in the 3  end. Even with such mismatches, the
RNAi mechanism can also promote translational inhibition.
The toleration of mismatches gives rise to the signiﬁcant
oﬀ-target eﬀects of potential RNAi therapeutic agents (see
below). In D. melanogaster embryo lysates, target annealing
and cleavage by RISC are both ATP-independent steps. It
is only the release of the target after cleavage that requires
ATP [75]. The expected increased catalytic eﬃcacy of RNAi
compared to ribozymes is most likely due to the increased
OFF rates of products that is facilitated by RISC. This step
may be slower in humans as the Drosophila RISC enzyme
seems to have a higher catalytic eﬃciency despite similar Km
values [77]. Recent studies indicate that the RISC complex
can be saturationally inhibited by other competing siRNAs
andthattheloading(1hr)andclearance(12hrs)oftheRISC
complexhavedistinctkineticrates[78].Whilethesuggestion
that RNAi is more potent than AS or Rz modalities, RNAi
still shares with all PTGS modalities the same major problem
of the intrinsic limits of target inaccessibility, with the
initial challenge being to identify rare accessible regions. Few
studies have compared RNAi potency to other modalities at
sites in target mRNAs that are predetermined to be accessible
or inaccessible in vivo. Even if intrinsic potency is greater for
RNAi, the potential for oﬀ-site and toxic eﬀects of RNAi may
make ribozyme or perhaps AS better choices for therapeutic
PTGS development.
Recent discoveries continue to reveal the complexity of
the machinery involved in the RNAi mechanism, and great
care must be taken to evaluate potential RNAi therapeutic
agents. For RNA therapeutics to be safe clinically, they must
have speciﬁcity. There are an increasing number of reports
about oﬀ-target knockdown eﬀects by RNAi [79–83], some
of which have induced toxic eﬀects [84]. This likely results
because of the tolerance of RISC to mismatches in bound
targetRNAsandadecreaseinspeciﬁcityforintendedtargets.
siRNA activation of interferon response genes has occurred
[85] as well as activation of the immune system [86]. Recent
serious concerns over RNAi safety were raised due to death
of mice secondary to RNAi saturation of a nuclear exit
pathway (exportin-5) used by micro-RNA [87–89]. Thera-
peutic interference with natural and essential functions of
micro-RNAs, such as diﬀerentiation, cell-cycle control, and
gene expression, could also cause serious deleterious conse-
quences.Theseﬁndingsraiseseriousconcernaboutpotential
toxicity of RNAi in human clinical trials. In addition to
oﬀ-target knockdown concerns, a recent study also revealed
the potential for sequence-independent knockdown of an
RNAi target unrelated to oﬀ-target immune eﬀects. Anti-
angiogenic siRNAs were targeted to VEGF or its receptor
for the treatment of choroidal neovascularization (CNV)
in age-related macular degeneration. The siRNAs showed
a suppression of CNV that was caused by a class eﬀect of
21-nucleotide double-stranded RNA sequences stimulating
cell-surface Toll-like receptor 3 that lead to an induction of
interferon-gamma and interleukin-12 rather than a speciﬁc
knockdown of VEGF or its receptor [90]. A siRNA database
is available for the interested reader [91].
Micro-RNAs (miRNAs) are noncoding regulatory RNAs
expressed in mammalian cells generally from RNA pol-II
promoters as primary miRNAs (pri-miRNAs). Pri-miRNAs
are processed in the nucleus by the endonuclease Drosha
to form pre-miRNAs, which are derivative hairpin RNAs
that are transported by Exportin-5 to the cytoplasm. There
they are further processed by Dicer into 21–23bp dsRNAs
that enter the RISC processing pathway. miRNAs con-
trol development, gene expression, cellular diﬀerentiation,
growth regulation, and many have been identiﬁed in human
cells [92]. miRNAs appear to be the native substrates of
the evolutionarily conserved RISC RNAi pathway. miRNAs,
like other RNAi modalities, can promote cleavage of target
mRNAs if there is full binding to the target mRNA, or trans-
lational inhibition when bound by seed sequences, but with
mismatches, to 3  UT sequences. Recent eﬀorts have sought
to create designer miRNAs in which a particular native
human miRNA, which is expected to have its own intrinsic
set of target mRNAs, is engineered to create potential for
annealing to a disease target mRNA. Early data suggest
that this approach may yield both potency and decreased
potential for toxicity, because lower levels of expression of
the miRNA are achieved [93, 94]. However, the design and
embedding of PTGS agents as chimeras within usurped
native human miRNAs that naturally interface through
RISC to modulate critical cellular functions may create
risk. More studies are needed to establish both eﬀectiveness
and safety of this approach. Clearly, miRNA evolution
achieved speciﬁc RNA structures that were processed and
reduced to functional siRNAs inside cells. The insertion of
an alternative nonnative targeting sequence into a larger
miRNA embraces substantial new biophysical constraints.
How can one insure that the targeting siRNA is properly
spliced from a larger RNA when multiple conformational
states of the miRNA chimera can exist and these might
aﬀect how Drosha and Dicer process the expected target
sequences?8 Journal of Ophthalmology
2. Variables andChallenges in Therapeutic
PTGSDevelopment
2.1. Overview. A PTGS agent is designed to suppress the
translation of a particular target mRNA into its cognate
protein. This may occur through tight annealing of the
PTGS agent to the target mRNA which stalls translation
at the ribosome. Or, it may occur through annealing and
cleavage of the target mRNA which promotes more rapid
degradation of the target mRNA, to decrease the steady state
concentration of the target mRNA and suppress translation
at the ribosome and hence the steady state level of the
cognate target protein. In the context of a therapeutic PTGS,
the particular mRNA/protein targets must be validated
for a given disease state, such as a retinal degenerative
disease. Validation means that the expression of the speciﬁc
target mRNA/protein has been strongly associated with the
emergence of a particular disease state. For example, in an
autosomal dominant form of hereditary retinal degeneration
such as retinitis pigmentosa, the expression dose of mRNA
from the mutated allele may generate a protein which has
toxic gain of function for the cells in which it is expressed.
This toxicity may promote stress and ultimately apoptosis.
At least, early in the disease process, it is rational to select the
mutated mRNA as the validated target for therapy of such a
genetic disease. If the mutant mRNA and toxic protein can
be reduced, this outcome is expected to ameliorate cellular
stresses and reduce the probability of apoptosis and the
coincident loss of cellular and visual function. Similarly, in
certain retinal degenerative conditions, such as age-related
macular degeneration, rational therapeutic PTGS strategies
could potentially involve the reduction of levels of wild-type
gene expression.
PTGS agents operate biophysically within the functional
context of cellular housekeeping functions to reduce levels of
speciﬁc target mRNAs and proteins. The critical variables in
the design of eﬃcacious potentially therapeutic PTGS agents
are not speciﬁc to retinal or other ocular diseases and in fact,
have largely emerged from research not speciﬁc to ocular
diseasestates.Therefore,wehaveattemptedheretorepresent
to the reader the biocomplexity of these challenges garnered
from the PTGS literature at large, because the rules identiﬁed
are equally relevant and essential for development of such
PTGS agents for human retinal or eye diseases. Hence, we
have speciﬁcally not attempted here to review the emerging
PTGS literature for retinal or ocular degenerations. Our
focus here is on the variables that inﬂuence development and
eﬃcacy of a PTGS agent itself (the drug or Rx) rather than
on the means of delivery of such an agent to the aﬀected cells
(e.g., through a vector or chemical design). When discussing
the core strategies for therapeutic PTGS development, which
did strongly emerge from early studies applying such agents
to hereditary retinal degenerations, we touch on studies that
lead to these strategies.
S u c c e s s f u ld e s i g no faP T G Sa g e n t ,b ei tA S ,R z ,o r
RNAi, involves biocomplexity at the biophysical, biochem-
ical, and cell biological levels. A target mRNA molecule
is folded into dense secondary and tertiary structure, it is
coated with heterogeneous proteins, it undergoes dynamic
conformational ﬂuctuations, and it resides in unique intra-
cellular compartments with diﬀerent lifetimes (nucleus,
cytoplasm, ribosomes, etc.). These target mRNA factors
severely constrain the locations in the RNA target that
are accessible to the annealing of a colliding small PTGS
agent and the range of timescales and spatial environments
available for small PTGS ligand attack. In addition, the PTGS
mustbeabletoachieveagroundstateconformationinwhich
it is fully available to interact with and anneal to exposed
regions of the target mRNA (molecular recognition). For
Rz PTGS agents, the catalytic RNA bound to the target
RNA must be able to undergo conformational transitions
that promote RNA chemistry-based target cleavage. The
structure-function properties of Rz-based PTGS agents
become especially diﬃcult when the Rz is embedded in a
larger chimeric RNA to provide cell traﬃcking, stability,
and high levels of expression. PTGS biocomplexity is a
multivariate problem that is a major factor in the slow entry
of nucleic acid knockdown agents into the pharmaceutical
market despite obvious clinical potential. RNA structural
biology greatly limits PTGS therapeutic strategies. In this
paper we present the variables that must be understood for
successful development of a PTGS agent. We present aspects
of target RNA biology that will convince the reader about
the biocomplexity of PTGS development. We present the dif-
ferent strategies and approaches of how PTGS agents can be
used therapeutically for hereditary and degenerative diseases
of the retina or eye and the relevant variables in the design
of materials for such strategies. While RNA-directed drugs
are still largely on the horizon, we brieﬂy describe some high
throughput screening (HTS) approaches that are expected
to greatly inﬂuence further development of PTGS agents.
Recent emergence of tools to address diﬃcult scientiﬁc issues
underlying the biocomplexity of the transcriptosome and
RNA structure/function oﬀer substantial hope that the dawn
of clinical translation of RNA-directed drugs is visible in the
near future. Use of HTS approaches to relieve bottlenecks in
PTGS development is dealt with in detail in a separate review
[95].
2.2. Common Variables That Aﬀect Eﬃcacy of PTGS Agents.
There are ﬁve critical variables that are essential to under-
stand in order to design PTGS agents that are eﬃcacious
in vivo. Limitation of any single property is suﬃcient to
completely obviate functionality of the PTGS agent. First,
the PTGS agent and its target RNA must be in the same
cellular locale or compartment in order to allow for potential
annealing interaction. Second, the PTGS agent must be in
suﬃcient concentration to drive an adequate second-order
collision frequency which is essential to secure annealing.
Third, the target RNA must present an accessible and
kinetically stable single-stranded platform at physiological
temperature in order for the PTGS agent to anneal. Fourth,
the PTGS agent itself must be in a conformational state that
permitsdirectandfullannealingtothetargetRNA. Fifth,for
Rzs and RNAi, the cleavage products must dissociate rapidly
from the enzyme to insure potential for enzymatic turnover
(Michaelis-Menten kinetics).Journal of Ophthalmology 9
2.2.1. Colocalization. In all cases, the PTGS ligand and the
targetRNAmustcolocalizeinpreciselythesamespatialenvi-
ronment within the living cell, and on the same timescales,
to support frequent collisional interactions that may result
in kissing complex formation and full annealing [96–98].
RNAs (both target and PTGS agent) move along traﬃcking
streams inside the human cell and have lifetimes at each
stopping point along the way to their ﬁnal destination(s).
Hence, expressed RNAs may distribute among diﬀerent
spatial locales within the cell. Most mRNA targets for PTGS
will spend the largest amount of their intrinsic lifetime in
the cytoplasm, where they are diﬀusing, translated on the
ribosome, or stored in RNA granules. While it is easy to
appreciate that a PTGS agent that traﬃcs to the nucleus will
be unable to eﬀect knockdown of a cytoplasmic mRNA tar-
get, more subtle issues are that both target mRNA and PTGS
RNA agent could be in the same macroscopic compartment
(e.g., cytoplasm) and yet not colocalize, because they do
not occupy the same cellular RNA zip code, or that the
lifetimes of the target and PTGS agent in a given locale are so
disparate that meaningful second-order collision frequency
is not probable. There are both gross macrocompartments
and microcompartments within those in which mRNA
targets and PTGS agents will need to colocalize for eﬀective
interactions. RNA zip codes are known to exist, and play
a role in cellular RNA traﬃcking, storage, or to sponsor
RNA: RNA interactions [99, 100]. The ideal situation for
gene therapy is if the PTGS agent is engineered to occupy
the same speciﬁc RNA zip code within cells as its cognate
target, and that the lifetime or stability of the PTGS agent
in the cell within the preferred locale is on the same order
or greater than the lifetime of the target mRNA in the same
spatial locale. In order to achieve colocalization with the
target mRNA it may be beneﬁcial to embed the PTGS agent
into a carrier RNA to create a chimera. The carrier RNA
(e.g., tRNA and VAI RNA) has established structure and
function,isexpressedtohighlevelsinthecell,andhasknown
traﬃcking properties that lend itself useful for colocalization
of the PTGS agent with its target. Embedding a PTGS
agent within a carrier RNA certainly adds to complexity of
structure/function of the PTGS agent, which is an area that
h a sn o ty e tr e c e i v e dm u c hi n v e s t i g a t i v ee ﬀort.
2.2.2. PTGS Concentration and Diﬀusion Limitations. The
PTGS agent must be present at suﬃcient concentrations in
the same cellular locale as the target RNA to allow a fast and
eﬀective diﬀusion-limited second-order ON reaction rate
(k1)withthetargetRNA.Whilewenormallythinkofenzyme
reactions in macroscopic terms, with the substrate in sub-
stantial excess (Michaelis-Menten condition), it is prudent
to consider the actual concentration of a target RNA inside
a cell. Target RNAs are typically expressed in low numbers
inside the cell. Even from a relatively strong promoter (e.g.,
human rod opsin) an estimated steady-state level of approxi-
mately 2500mRNA molecules resides in a cytoplasm of total
volume1.75picoliters(simplifying assumptionofaspherical
cell with 15μm cell diameter and spherical nuclear diameter
of 3μm and with no excluded cytoplasmic volumes) would
yield a steady-state concentration of 2.4nM. With weaker
promoters, 250mRNA molecules would yield a steady-state
concentration of 240pM, and 25mRNA molecules could
yield a concentration of only 24pM. Even when the target
mRNA is relatively abundant, these estimates indicate low
cellular concentrations for the substrates (targets) of an
initial PTGS annealing reaction. In addition to the target
mRNA being in low concentration, it is also expected to
be large with slow cellular diﬀusional coeﬃcients [101].
Hence, the PTGS agent must be expressed or delivered in
suﬃcientconcentrationsinthecorrectcellularcompartment
to promote an eﬃcient collision rate with the target mRNA
in order to promote a rapid second-order annealing reaction
[102, 103]. The time scale needed for the functionality of
the PTGS must also be embraced. For example, a rapidly
degraded and intrinsically short lived mRNA that codes
for a short lived protein involved in cell cycle regulation
(e.g., a transcription factor), may have a half-life on the
order of minutes and be expressed in low concentrations. It
would be diﬃcult for any PTGS technology to modulate the
knockdown of such an mRNA and protein simply, because
thekineticactionoftheagent(e.g.,RzandRNAi)maybetoo
slow to modulate an intrinsic process of mRNA degradation
that is already rapid (kcat = kint + kPTGS ∼ = kint).
2.2.3. Target Accessibility. Regardless of the experimental
approach, large bonaﬁde regions of stable accessibility in
target RNAs are rare in RNAs of any substantial size. The
biocomplexity of the RNA target is the prime and profound
limiting variable in the successful design of PTGS agents.
It is the factor that limits successful PTGS design of any
type(AS,ribozyme,RNAi)[104].Thesecondaryandtertiary
structures of the folded mRNA impose a severe limitation to
identifying suitable accessible regions for PTGS attack.
For any PTGS agent to be successful it must be able to
collide with and anneal to accessible regions of the target
mRNA. All successful PTGS technologies require bonaﬁde
regions of accessibility in the target RNA at 37◦Cf o rh u m a n
therapeutics. Regions that are inaccessible, due to overrid-
ing RNA secondary and/or tertiary structure, or protein
binding, will not permit rapid annealing, thus leading to
delays in hybridization during the waiting time for local
melting of secondary and tertiary structures at physiological
temperature, if such melting is thermodynamically feasible
(Figure 4) .A n yd e l a y sw i l ld e c r e a s et h eo v e r a l lo b s e r v e d
catalytic rate (kcat), and thereby reduce the amount of target
mRNA that is cleaved within a given time interval such that
target protein knockdown is limited. The capacity of the
PTGS to anneal is not only dependent upon a kinetically
stable accessible single-stranded platform, but also proper
orientation for annealing of the accessible platform in the
target mRNA to the approaching PTGS ligand in collisional
reactions at physiological temperatures. The biophysical
nature of the second-order annealing reaction between
ligand and target RNA is critical to success but often
unconsidered.
ThebiocomplexityofRNAtargetstructureistheprimary
and dominant variable in the success of a therapeutic10 Journal of Ophthalmology
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Figure 4: Secondary and tertiary structure as a limiting variable in PTGS eﬃcacy. Energy diagrams are presented for both the target mRNA
and the PTGS agent. The folded target mRNA has a site targeted for annealing which is buried in secondary or tertiary structure. The rate
of unfolding of this region is determined by the activation energy required for conformational transition that leads to accessibility of the
annealing platform. For the folded target RNA to be accessible it must present a single-stranded annealing platform(s) at its surface to
allow annealing with the PTGS agent upon intermolecular collision. Buried regions of the RNA that are targeted must wait at physiological
temperatures for relaxation of secondary and tertiary structure in order to present an annealing platform. Many regions are expected to
never be exposed. The Arrhenius rate provides an estimate of how long it takes for a single-stranded platform to emerge at physiological
temperature (310◦K = 37◦C) and is dependent upon the activation energy (Ea) of the transition. Likewise, any internal secondary structure
of the PTGS agent itself can prevent annealing to target or slow catalysis and impact eﬃcacy. Melting of inhibitory secondary or tertiary
structure in the PTGS agent then can allow exposure of the antisense ﬂanks to support annealing to the target mRNA.
PTGS agent. Large, accessible, and kinetically stable sites are
rare and expected to follow Poisson distribution statistics.
Therefore, initial eﬀorts in any PTGS study should embrace
the challenge to ﬁnd the most accessible sites in the target
mRNA. In any average size mRNA target, there are too many
potential sites to try and attack with any PTGS technology
and orders of magnitude insuﬃcient resources to test them
all. It is essential to be highly selective if one wants to achieve
a PTGS agent that can be brought into preclinical trials
in animal models. The ﬁrst question is how to successfully
identify accessibility in a target mRNA? We will discuss
several possible means including emerging technologies. It
is prudent to represent the complexity of the target RNA.
For the sake of demonstration, we will consider two human
mRNA disease targets for candidate therapies for autosomal
dominant diseases. Human rod opsin (RHO)a n dh u m a n
bestrophin (BEST-1) mRNAs are suitable examples. Both
are the subject of over a hundred mutations that cause
human retinal degenerative diseases. Most mutations in
the RHO gene cause autosomal dominant or autosomal
recessive retinitis pigmentosa and less commonly autosomal
dominant congenital stationary night blindness or retinitis
punctataalbescens[105,106].MostmutationsintheBEST-1
gene cause juvenile autosomal dominant vitelliform macular
dystrophy (Best disease) and less commonly autosomal
dominant adult vitelliform macular dystrophy or dominant
bull’s eye maculopathy [107–109]. The size of the dominant
polyadenylated transcripts in the retina are 1.8 and 2.2kB,
respectively, [110, 111]. These mRNAs targets are of average
size. The RHO gene is expressed exclusively in human rod
photoreceptorsintheretinathatprovidedimlight(scotopic)
vision, and the BEST-1 gene is expressed exclusively in the
retinal pigment epithelium.
There are several computational and experimental
approaches that can be applied to the determination of
accessible sites in RNA targets (Table 2). ComputationalJournal of Ophthalmology 11
Table 2: Methods to identify accessible sites in target RNAs.
Method Type Properties References
MFold IS
Algorithm ﬁnds minimal free energy (MFE) structure and set of
lower energy structures. Display as pictorial structures or output as a
single-stranded frequency map vector (probability estimator).
[14–17, 22, 95,
112, 113, 124,
125, 128, 211,
223, 224]
SFold IS Algorithm searches all of folding space and samples on basis of free
energy and determines probability of access directly. [128, 221]
OligoWalk IS
Algorithm takes output from MFold (.CT ﬁle) and uses this to
determine local target unfolding energy, ligand binding energy, and
net energy.
[25, 222]
mppRNA IS
Uses MFold, SFold, OligoWalk, and in-house processing model to
predict net probability of access in a region and to rank order the
outcomes based on several parameters.
[95, 113, 128,
136, 211, 221]
ODN: RNaseH EX
Search combinatorial ODN library for those entries able to bind to
target RNA on basis of RNaseH of RNA: DNA hybrid, followed by
primer extension analysis. Gel-based and cumbersome.
[14, 15, 31, 123–
125, 225–227]
ODN arrays EX
AS ODN sequence overlapping arrays are tiled onto silicon surfaces.
Labeled target RNA is bound under deﬁned conditions. Target
binding to regions of the array identiﬁes accessible regions.
[18, 228, 229]
Rz library EX
Rich combinatorial library of hhRz sequences was used to cleave
target RNA. First strand cDNA primed by Oligo-dT was followed by
3  dG tailing, followed by PCR with a downstream gene-speciﬁc
primerv and a poly-dC allowed ampliﬁcation and sequencing to
determine cleavage sites.
[136, 230–233]
RT-ROL EX
Uses probe for reverse transcription that has 3  randomized region to
screen for accessibility and constant region for PCR. Gene-speciﬁc
upstream primers allow agarose gel-based mapping of accessible sites
for antisense or ribozymes. Requires concurrent sequencing analysis
for mapping.
[234]
RT-TDPCR EX
C l e a v a g eb yA So rR z si sf o l l o w e db yR T ,3  cDNA tailing, and then
PCR using a tail-speciﬁc primer and a downstream gene-speciﬁc
primer. Very sensitive.
[235]
cMARS EX
Uses probe for reverse transcription that has 3 antisense to all NUH↓
hhRz cleavage sites, followed by randomized region to screen for
accessibility and 5  constant region for PCR. Gene-speciﬁc upstream
primers allow agarose gel-based mapping of accessible hhRz cleavage
sites and their relative accessibility.
[95, 211]
MAST EX
ODN with upstream and downstream constant regions embracing
region of randomized sequence. Constant regions clamped by
annealing complements. ssDNA region of MAST tags probes RNA
target attached to beads. Annealing followed by washing, probe
displacement, PCR, and sequencing. Little capacity to discriminate
signal from noise.
[236]
gsMAST EX
Reﬁned version of MAST in which the library is gene-speciﬁc or
sequence-speciﬁc MAST tags against a target RNA are evaluated in
competitive hybridization assay.
[95, 211]
Notes: cMARS: cDNA mapping of accessible ribozyme sites; EX: experimental (method); IS: in silico (method); gsMAST: gene-speciﬁc MAST; MAST: mRNA
accessiblesitetagging;mppRNA:multipleparameterpredictionofRNAaccessibility;RT-ROL:reversetranscriptionwithrandomODNlibraries;RT-TDPCR:
reverse transcription, terminal transferase-dependent PCR.
approaches are based upon algorithms that predict struc-
tures or energy, such as MFold, SFold, and OligoWalk
[112]. The interested reader can explore the references
associated with the diﬀerent methods detailed in Table 2.
Computational algorithms are available to predict RNA
secondary structure. Algorithms such as MFold [113] or the
older version RNAFold can be used to obtain images of
the secondary structure of a target mRNA. These speciﬁc12 Journal of Ophthalmology
algorithms search for the most stable structure with the
minimal (most negative) free energy (MFE). MFE secondary
structures of human RHO and BEST-1 mRNAs are shown
(Figure 5). Both mRNAs demonstrate densely folded MFE
secondary structures. There are rare single-stranded loops of
signiﬁcant size (e.g., >10nt). This is a common appearance
for all RNAs that we have folded computationally. There
is always dense secondary structure present, and at best
only rare regions containing large single-stranded platforms
are present that appear suitable for rapid annealing. We
have encountered RNAs that are even more densely folded
than those presented here. These represent single-structure
snapshots of the folding states of the mRNAs. There are
many other potential structures and these MFE structures
may not be the native structures in the cell. Nevertheless,
even from this simple computational presentation target
mRNA accessibility is clearly a dominant limiting variable in
design of eﬃcacious PTGS agents. Experimental approaches
assessing accessibility support this perspective as well.
Cleavage with intended target site speciﬁcity requires
that AS, hhRzs or RNAi be directed to accessible single-
stranded regions where rapid annealing and generation
of the enzyme: substrate complex equilibrium can occur
[46, 75, 114–116]. Rapid binding/displacement equilibrium
with a signiﬁcant kOFF rate allows mispaired mRNAs to
be released before cleavage, which generates speciﬁcity for
intended targets. Stabilized annealing complexes occurring
at oﬀ- t a r g e tm R N A sw i l ld e c r e a s es p e c i ﬁ c i t y .O n ew o n d e r s
if the speciﬁcity problems reported for AS [117] and the
promiscuous speciﬁcity of RNAi modalities somehow relates
to cellular protein-based stabilization (e.g., through RNaseH
o rR I S C )o fm i s m a t c h e dt a r g e t - P T G Sl i g a n dc o m p l e x e s .
The second-order annealing reaction appears to be the
rate limiting step for PTGS agents in the living cell for long
lived target mRNAs, and typically requires ten- to several
hundred-fold molar excess of ligand over substrate mRNA
to achieve good gene suppression [45, 96, 97, 114, 118]. This
factor is likely due to the cellular reaction occurring under
diﬀusion-limited conditions. While PTGS agent delivery,
expression load, and colocalization with target RNA will
aﬀect collision encounter frequency, the major initial barrier
to intracellular PTGS action is higher order target RNA
structure that globally restricts the number of access sites
[22, 119–125]. The secondary and tertiary structure obstacle
is expected to pose the most serious limitation to the
developmentofPTGStreatmentstrategiesfordiversegenetic
or non-genetic diseases (see [126, 127]).
2.2.4. PTGS Conformation. The PTGS agent must itself be
in a conformational state(s) supportive of the second order
annealing reaction in order to achieve successful target
knockdown [37]. Any abnormal intramolecular structure of
the PTGS agent itself will create potentially unrecoverable
annealing delays (Arrhenius rate of activation) and cause
loss of eﬃcacy for a constant ratio of PTGS agent to target
mRNA (Figure 4). Regions of self-complementarity within
a single-stranded AS ODN or hhRz RNA can occlude the
antisense ﬂanks from being freely available to interact with
the target mRNA. For a hhRz, it is also possible that the AS
ﬂanks intrude into the catalytic domain or into a structured
domain (e.g., Stem II). Any perturbation of structure is
expected to be potentially deleterious to both annealing and
catalytic function. Waiting for such secondary structures to
open at physiological temperatures implies an additional
rate of reaction that acts to eﬀectively slow the association
rate with target mRNA. Since the minimal hhRz has only
4 b po fd o u b l es t r a n d e ds e c o n d a r ys t r u c t u r ee x p e c t e df o r
the entire active enzyme, it is not surprising that alternative
conformational states of the hhRz can have marked impact
on catalytic eﬃciency. Attempts to stabilize the hhRz into a
proper secondary structure by extending Stem II or adding
a stabilizing loop to cap this stem have not lead to improved
function[128,129],perhapsbecauseextensionofStemIIhas
negative impact on the catalytic cleavage rate of the enzyme.
Proper structure as well as ﬂexibility may be important
for function. For the hhRz, the structure/function problem
becomes more challenging with the recent identiﬁcation of
5  tertiary accessory elements that form pseudoknots with
the Stem II loop and enhance the probability of achieving an
enzymatically active state [130–135]. These considerations
are focused on the ribozyme sequence itself. If the ribozyme
is embedded in a chimeric RNA for strong expression,
appropriate cellular traﬃcking for colocalization with target,
and overall stability and lifetime in the cell, the potential
for misfolded structures becomes much greater and requires
careful rational design for the placement of the PTGS agent
within the chimeric RNA (e.g., [136]).
2.2.5. Product Leaving. AS requires long hold times (high
aﬃnities) and hence must be highly stable once hybridized.
For AS, a highly stable ES complex must form in order to
attract RNaseH for cleavage, and it is necessary to identify
stable,accessibleregionsforPTGSwithinthiscellularmilieu.
R z sm u s th a v es u ﬃcient holding time to permit cleavage
but cannot bind too tightly or both loss of speciﬁcity for
the intended target and product inhibition will occur. Upon
cleavage, the upstream and downstream target products
must be cleared rapidly from the AS ﬂanks if the hhRz is
to have substantial enzymatic turnover of additional target
mRNA molecules. Similarly, RNAi requires suﬃcient hold
time for RISC-mediated cleavage and must clear products
to promote eﬃcient multiturnover catalysis. For both hhRz
and RNAi, too long a hold could be deleterious to speciﬁcity
and contribute to oﬀ-target eﬀects. RNAi is much more
susceptible to oﬀ-target eﬀects, because the RISC complex
is highly tolerant of mismatches with target [75]. RISC
in mammalian cells appears to use an ATP-dependent
helicase to aid in stripping products, and this gives RNAi
an advantage over native ribozymes which depend upon
thermal solution properties (kT) for product release. In
addition, the RISC complex is strongly dependent upon a
relatively short “seed” sequence (6-7nt) within the 5  end of
the guide RNA, which would be expected to interact with a
largersetoftargetswhencomparedtotheentirelengthofthe
siRNA (e.g., 19–23nt). A Rz or RISC that cannot dissociate
from the cleaved products of reaction becomes a catalyticJournal of Ophthalmology 13
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Figure 5: Predicted minimal free energy folding structures of human rod opsin and Bestrophin-1 mRNAs. GeneBank accession numbers
for human rod opsin mRNA (NM000539.2) and Bestrophin-1 mRNA (NM004183) are indicated. (a) Human rod opsin mRNA (1–1820nt)
was folded in silico with RNA-Fold. The minimal free energy structure is shown. Note the dense secondary structure with only rare single-
stranded annealing platforms of any substantial size. Also shown are the locations of human missense mutations that cause autosomal
dominant retinitis pigmentosa and that generate new hhRz cleavage sites. These are mostly buried in secondary structure, where they would
be poor targets for a mutation-speciﬁc (MSpe) approach to gene therapy as the PTGS agent would have limited capacity to anneal and cleave
only the mutant target mRNA. (b) Human bestrophin-1 mRNA (1–2000nt) was folded with RNA-fold and the MFE structure is shown.
Again, secondary structure is dense with rare single-stranded annealing platforms larger than 10nt. The locations of human mutations that
cause autosomal dominant best macular dystrophy and that generate new hhRz cleavage sites for a mutation-speciﬁc strategy are shown
(MSpe). Most are buried in dense secondary structure, where they would be expected to be inaccessible to annealing of a PTGS agent. Also
shown are some mutations located in regions of WT cleavage sites, where they would permit a mutation-selective (MSel) approach to PTGS
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antisense reagent without capacity for enzymatic turnover.
Product leaving rates must be robust in order to clear the
annealing or loading sites to promote next-target annealing.
Product leaving rates can be predicted based upon nearest
neighbor energetic analysis, which is prudent in early PTGS
design (e.g., [13]).
2.3. Summary. The above variables lead to strong directives
in approaches to PTGS design. The steady state level of
a target mRNA is experimentally invariant as a deﬁned
characteristic of a particular target cell. The only way to
inﬂuence the eﬀective statistical collision frequency of the
PTGS agent, whether in a deterministic or stochastic process,
is to increase the numbers of PTGS ligands immediately
within the local environment of the target and to keep
those ligands relatively small such that they have substantial
diﬀusional rate relative to the larger target RNA (expected to
have a slower diﬀusional rate in the cell). Smaller size of the
PTGS agents can also facilitate probing of targets in which
the annealing site is found in recessed surface features of the
tertiary structure. Successful knockdown of target requires
both strong promoters and appropriate traﬃcking of the
PTGS agents into the diﬀuse or speciﬁc microenvironments
in which the target RNA resides inside the cell (e.g.,
knowledge of target RNA zip codes and the capacity to
integrate this into the PTGS strategy). The PTGS agent must
be stable, resist nucleases, and have a long cellular lifetime
in the appropriate cellular compartment. The accessibility
of the target mRNA must be rigorously determined if any
successful target suppression is to occur. Regions of the
target that present large, stable, single-stranded annealing
platforms appear to be optimal, but these sites are typically
rare in any target RNA. The PTGS agent must be able to
appropriately sample necessary conformational transitions
to achieve its activity, an issue which is especially challenging
for an Rz and especially when the Rz is embedded in a
chimeric RNA. For an Rz or RNAi the binding to the
target must be suﬃc i e n tb u tn o tt o ot i g h ti no r d e rt o
achieve maximum speciﬁcity and to allow product release
thatisnecessarytosupportenzymaticturnover.Inaggregate,
these variables create rational engineering and experimental
challenges which must be embraced simultaneously to
achieve eﬃcacious PTGS agents for candidate therapeutics.
This multivariable problem is a major reason why the entry
of PTGS into the therapeutic landscape for human disease
has been so slow.
3. Strategies and Approaches for PTGS Therapy
There are several types of therapeutic strategies that might
be used for PTGS by any technological modality. The choice
may depend upon whether the disease process is genetic in
originandwhetherthetargetmRNAorviralRNAcodesfora
normalormutantprotein.Thesestrategiesare(1)mutation-
independent or knockdown, (2) RNA repair, (3) mutation-
directed, and (4) combined therapy. By example, we will
discuss here the diﬀerent types of strategies as they might be
applied to human retinal (or ocular) diseases, which is this
labsvenueofinterest.Thegenericknockdownapproachmay
also be used to suppress wild-type mRNA expression [137].
3.1. Knockdown Therapeutic Approach. The mutation-
independent or knockdown (KD) approach is the most
straightforward. This strategy is used to suppress or knock
down a target mRNA and its cognate protein. The target
mRNA may be overexpressed from wild-type (WT) genes
in particular clinical conditions or may be expressed in
normal amounts but a therapeutic beneﬁt can be envisioned
from target suppression, or the target could be a viral RNA
essential to a viral life cycle. KD may also be used as a
component of combined PTGS therapy for genetic diseases
(see below). The initial goal with KD is to identify the single
most accessible site(s) of the WT target mRNA or viral
RNA. Once this site(s) is identiﬁed then PTGS agents (AS,
Rz, and RNAi) can be designed to anneal at these regions
and promote target RNA knockdown within the live cell.
AS ODNs are typically transfected into cells of a particular
type, where the target is expressed and where the disease
process is manifest. Rzs or siRNAs RNAs may also be directly
transfected into cells. More commonly, Rzs, shRNAs, or
miRNAs are transcribed from plasmid or vector constructs
by RNA polymerases (Pol-II or Pol-III) within the cell
harboring the target RNA. Expression constructs for the
PTGS agent are delivered into cells by transfection agents,
viruses, or nanoparticle systems (synthetic viruses).
3.2. Gene Therapies for Dominant Mutations. The molecular
genetics of inherited retinal degenerations is very well
developed and provides a suitable example. Many mutations
inhumangenesthatareexpressedintheeyecauseautosomal
dominant disease patterns. Autosomal dominant hereditary
retinal and macular degenerations are caused by mutations
in genes expressed in speciﬁc cell types of the human
retina [138, 139]. At least 204 retinal disease genes have
been mapped, and 161 of these genes are cloned in part
due to highly eﬀective candidate gene approaches and the
Human Genome Project and a database is available (RetNet,
[140–142]). However, the RetNet database of disease genes
underestimates the gene therapy challenge because multiple
disease-causing mutations are commonly found in any
given gene. The number of mutations can extend into the
hundreds. Relevant examples are the many (>120) human
rod opsin gene (RHO) mutations identiﬁed, since the P23H
mutation was found causally associated with adRP. Opsin
mutations are estimated to be responsible for 25%–30% of
all cases of adRP [105, 106, 138]. Mutations in the RHO gene
cause adRP, autosomal recessive RP, ad congenital stationary
night blindness, and retinitis punctata albescens. The RHO
gene, therefore, oﬀers a robust model to investigate the extent
to which PTGS therapies can be broadly applied as human
gene therapies for ad retinal degenerations. The VMD2 or
Best-1 gene is another robust example. VMD2 is mutated
in Best’s vitelliform dystrophy and adult foveovitelliform
dystrophy and has been found to harbor at least a hundred
mutations, with almost all of these being dominant in
nature. One can expect the general trend that the number ofJournal of Ophthalmology 15
mutations identiﬁed increases with time after identiﬁcation
of the disease gene.
3.2.1. Mutation-Independent or Allele-Independent Approach.
The mutation independent (MI) or KD approach in its
stand alone format may be suﬃcient to suppress the
disease process in a dominant genetic disease provided
that no haploinsuﬃciency results. In a dominant hereditary
condition, one can expect approximately 50% WT and
50% mutant protein expression from the two alleles. Often,
in the normal case (no mutations), the WT protein is
expressed in excess over that needed for cellular functions.
In the autosomal dominant condition, the WT protein is
already reduced by approximately 50%. This may already be
insuﬃcient to support cellular metabolism in the absence
of the mutant protein (haploinsuﬃciency). In an MI or
KD approach, the best PTGS agent is identiﬁed to target
the most accessible site in the target mRNA to achieve the
greatest degree of target mRNA/protein suppression. In this
strategy, there is no speciﬁcity for the mutant mRNA versus
the WT mRNA. Knockdown of mutant protein expression
is expected to ameliorate the cellular toxicity that results
from protein misfolding, or gain-of-function properties
of the mutant protein, and thus relieve cellular stresses
and permit longer cell vitality or normalization of cellular
function. However, the MI or KD PTGS agent will also
reduce WT protein expression below 50%, and this could
promote haploinsuﬃciency and cell stresses and even cell
death as a result. Thus, the MI or KD approach, as described
above for WT targets, may possibly be used in autosomal
dominant hereditary conditions, provided that the cell can
resist haploinsuﬃciency due to further reduction of WT
protein. If the relief of cellular stresses due to a highly toxic
mutantproteincancomeaboutbyrelativelysmallreductions
in mutant and WT protein, the impact of haploinsuﬃciency
may not play as strong a role in cellular vitality.
3.2.2. mRNA Repair. mRNA repair has been described with
the use of the large trans-splicing Group I intron ribozyme
of Tetrahymena that has been under development by the
Sullenger and Haseloﬀ labs [143–153] (Figure 6). The
concept behind mRNA repair is that the guide sequence of
the Group I Rz is engineered to anneal to a region of the
target mRNA just upstream of the location of the mutation,
cleave the RNA while using an available free guanosine as
the nucleophile, release the downstream cleavage product,
and ﬁnally trans-splice a normal 3  exon onto the 3  end
of the upstream element of the target. All mutations in
a target gene downstream of the cleavage splice site can
thus be repaired. This makes mRNA repair an MI strategy.
The engineered Tetrahymena Rz is actually a chimeric RNA
and contains the Rz sequences, the guide sequence which
is antisense to the target mRNA region, and an appended
sequence which is the WT version of the target mRNA from
just upstream of the site of mutation(s). The goal of mRNA
repair is to cleave the target mRNA just above the site(s) of
mutation and to splice onto the 3  cleavage end an in-register
copy of the downstream component of the WT mRNA. The
ribozyme splices itself out during this process. In this two-
step process a WT mRNA is produced. This strategy could
be used to repair all mutations downstream of the site of
targeting. Therefore, just a few sites of targeting might be
used to repair most or all known mutations in a given disease
gene. A major disadvantage of this approach is that only a
short guide sequence in the Rz (6nt) is used to recognize
the target RNA. This has resulted in lack of speciﬁcity
regarding oﬀ-target mRNAs. Recently, the antisense region
was extended to improve speciﬁcity against the intended
target, and other elements of the Rz were optimized to
generatebettereﬃciencyoftrans-splicing.AsforotherPTGS
strategies, the site of targeted annealing for trans-splicing
has been found to be substantially aﬀected by the secondary
and tertiary structure of the mRNA in mammalian cells.
Therefore, to be able to handle all or most mutations in a
given gene, several accessible sites in the target will generally
be necessary or a single accessible upstream target may be
suﬃcient. While this speciﬁc MI approach by mRNA repair
is more complex relative to other modalities (e.g., hhRz,
RNAi), RNA repair still has potential to become clinically
useful [147, 154]. One limit is that multiple agents will likely
need to be developed to handle sets of mutations in a given
gene, unless an upstream accessible region can be used for all
mutations in a given gene. Another important issue is that
the engineered Group I intron is spent for each mRNA that
is repaired. There is no target turnover as one would have
witheitherRzorRNAiagentsoperatingasMichaelis-Menten
PTGS agents. Once the RNA repair enzyme operates on a
single target that ribozyme no longer has a 3  WT region to
append to a subsequent target.
3.2.3.Mutation-DirectedStrategies. Mutation-directed(MD)
therapeutic strategies target only the mutant mRNA with
the intent of leaving the WT mRNA intact. MD PTGS
agents have been shown to have therapeutic potential to
stablyrescuephotoreceptorsfromtoxicmutantopsinprotein
expression manifest in a transgenic adRP rat model, albeit
only a small fraction of mutant mRNA was suppressed
[155, 156]. First, we detail the speciﬁc uses of a MD strategy,
and then, we will present the advantages and substantial
disadvantages which we expect will limit its use in gene
therapy. There are two means by which a MD strategy
might be realized, which depend upon the nature of the
mutation and the nature of the PTGS technology utilized. In
a mutation-speciﬁc strategy (MSpe) PTGS agents selectively
inhibit mutant genes by targeting only mutant mRNA for
cleavage. MSpe PTGS can easily be embraced by hhRz
technology given the high degree of speciﬁcity of cleavage of
the target mRNA at NUH↓ sites. To be susceptible to a MSpe
strategy, the mutation in the gene must create a new cleavage
site that is not present in the WT mRNA. For example,
consider the human RHO mutation G51V (GGC → GUC↓).
The mutation at the gene level is a transversion converting a
GtoaTresidue(orUforRNA).Thiscodingregionmutation
converts a glycine codon to a valine codon and generates a
newhhRzcleavagesite(GUC↓).Thiscodingmutationresults
in a mutant protein, when expressed with WT protein, that16 Journal of Ophthalmology
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Figure 6: mRNA repair strategy for Dominant Mutations. The trans-splicing group I intron of Tetrahymena is engineered with an element
that contains a WT mRNA sequence starting from just upstream of the mutation(s) in the target mRNA (labeled X). The Group I intron
recognizes the region upstream of the target by way of complementary base pairing. It then cleaves the target using free guanosine as a
nucleophile and then trans-splices a fresh downstream WT target mRNA element at the precise site of cleavage. All mutations in a given gene
below the splice site could be treated with a single trans-splicing group I intron. One or several engineered group I introns could cover most
mutations in a given human gene.
leads to photoreceptor stress and ultimately apoptotic cell
death in adRP [157–161]. The mutant protein could inhibit
appropriate expression or traﬃcking of the WT protein
(dominant negative mutation). It is possible that this speciﬁc
mutationleadstoaproteinthatisunstableinthatitmisfolds,
is targeted for ubiquitination, and is then degraded by the
protesome. Such a result in general could lead to haploinsuf-
ﬁciencyastheassumed50%ofWTgeneproductthatismade
stably by the cell in a dominant hereditary condition may
be insuﬃcient to build the necessary multiprotein structure,
create suﬃcient enzyme activity, or maintain the capacity of
a signaling pathway. On the other hand, this mutation could
promote a gain of function. Gain of function mutations
could act at many levels. Such a mutation could create in the
proteinnonfunctionalmisfoldedstatesthatarenotprocessed
in large part for degradation, but rather become trapped
in the endoplasmic reticulum, where they can accumulate
and activate the unfolded protein response to exert toxicity
and promote apoptosis [162–171]. On the other hand, the
mutant protein might fold normally but mistraﬃc to the
wrong compartment in the cell and exert signaling events
thatareagainoffunctionthatistoxic tothecell(e.g.,[172]).
The mutant protein may fold and traﬃcc o r r e c t l yb u th a v e
some intrinsic instability that results in aberrant interactions
with other proteins or aberrant signaling events that are
also gains of function (e.g., [173]). Or, the mutant protein,
in its interactions with other macromolecular components
or the WT protein itself, aﬀects the processing, traﬃcking,
structure building and functional expression levels of the
WT protein and thus have a dominant negative inﬂuence
[174–176]. The possibility of the mutant protein creating a
haploinsuﬃciency, gain of function, or dominant negative
eﬀects has substantial impact on PTGS strategies. Haploin-
suﬃciency is treatable with a WT allele. Dominant negative
eﬀects might be treatable with a WT allele but may also
require mutant protein knockdown. Gain of function eﬀects
certainly requires mutant protein suppression. It is appro-
priate to consider potential therapeutics in terms of whether
they require WT protein reconstitution, or alterations in the
relative ratio of WT to mutant mRNAs and proteins.
Returning to the RNA targets, the WT mRNA triplet
GGC does not represent one of the classical NUH↓ sites for
the hhRz, but the new GUC↓ motif is not only a classical
triplet, but is also one of the two naturally occurring NUH↓
sites (GUC↓,G U A ↓) with high intrinsic cleavage rates. The
mutation creates a new hhRz cleavage site in the mutantJournal of Ophthalmology 17
mRNA, while the WT mRNA has no cleavage site at the same
position. This is the necessary and suﬃcient condition for use
of the MSpe strategy. Such a mutation creates opportunity
to design an MSpe hhRz intended to cleave only the mutant
mRNA while leaving the WT mRNA intact, because it lacks
the new NUH↓ site [177, 178]. The mutation could occur
at any position in the gene (5 UT, coding, 3 UT) and still
allow an MSpe strategy so long as a new NUH↓ cleavage
site is created. Such a stand-alone strategy only makes sense
for autosomal dominant mutations. On face value, the MSpe
strategy seems ideal given that it allows a speciﬁc attack of
a PTGS agent only on the mutant mRNA to suppress the
mutant disease protein. However, there are a number of
substantial limitations to the MSpe strategy. First, the MSpe
strategy would only be indicated when there is a toxic gain
of function of the mutant protein in the cell in which it is
expressed. Second, only a fraction of mutations that occur in
a given disease gene would create new hhRz cleavage NUH↓
motifs required for MSpe design. For example, of the 124
human rod opsin adRP mutations that we have tabulated
relatively few (∼21%) create new NUH↓ cleavage motifs for
hhRzs.Similarly,ofthe108humanVMD2mutationsthatwe
have tabulated, only 15% create new NUH↓ cleavage motifs
for hhRzs. Third, there is variation in the intrinsic rate of
cleavage of NUH↓ motifs and some of these (e.g., AUA↓)
have cleavage rates up to several orders of magnitude slower
than those that occur in nature (GUC↓,a n dG U A ↓)[ 43].
Fourth, even though the MSpe hhRz would be designed to
cleave the new NUH↓ site created by mutation, most of the
two antisense ﬂank regions will precisely anneal to the WT
target mRNA; this could result in a substantial antisense
eﬀect against the WT mRNA and contribute to an already
preexisting haploinsuﬃciency eﬀect due to the dominant
mutation [178]. These factors alone would strongly limit the
overall applicability of the MSpe approach for ad mutations
inanygeneexceptthosethatgeneratenewrobust hhRzcleav-
age sites. Fifth, random single-nucleotide mutations which
constitute the bulk of human mutations are expected to
mostly reside in regions of dense secondary structure, and be
largely inaccessible for targeting. The expected lack of acces-
sibility in the target mRNA around sites of most mutations is
likely to be a single major factor that limits development of
MSpe hhRz strategies. Sixth, each MSpe mutation requires
an independent discovery and drug development process.
The practical costs of such an eﬀort are prohibitive.
A mutation-selective strategy (MSel) expands upon the
limitations of the MSpe strategy [155, 179]. MSel hhRzs are
designed to cleave at active NUH↓ sites (e.g. GUC↓,G U A ↓,
GUU↓, UUC↓,C U C ↓,a n dA U C ↓) that are adjacent to or in
the immediate vicinity of the mutant codon. However, these
cleavage sites are also present in the WT mRNA. This limits
speciﬁcity (hence mutation selective), as some cleavage of
WTmRNAwilllikelyoccur,inadditiontotheantisense(AS)
eﬀect on the WT mRNA that is expected to result from hhRz
annealing [178]. The MSel rationale for development of an
hhRz PTGS agent is that perfect hhRz annealing to mutant
mRNA will lead to its selective cleavage, while mismatches
between the hhRz and WT mRNA at N1,N 2 or N3 in the
sequence N1N2(NUH↓)N3 (H does not base pair to hhRz)
will impair the cleavage rate for the WT mRNA (≥500-fold
for an N3 mismatch = Strong MSel; ≤10-fold for an N1
or N2 mismatch = Weak MSel) due to an expected hhRz
structural perturbation [47, 180]. Strong MSel hhRzs can
target ∼9% of opsin adRP mutations, so we group them
intoastrongMDstrategy(therapeuticpotentialfor ∼24%of
mutants). All of the other disadvantages seen with the MSpe
approach are also expected for the MSel approach, the most
signiﬁcant being target mRNA structure which will severely
limit annealing at most sites of human mutation. In all MD
strategies, the Rz is obligated to anneal to local primary
sequence around the site of a random human mutation asso-
ciated with an NUH↓ motif. Most single nt ad mutations in
any mRNA will predictably localize to hybridized secondary
structure which is expected to limit or frankly block Rz
annealing at the vast majority of potential cleavage sites (see
Figures 5, 7). For example, attempts to develop mutation
speciﬁcorselectiveribozymes tothehumanrodopsin P347S
mutant mRNA have failed in vitro [181].
AllMDstrategiesofPTGSforgeneticdiseasesrequirethe
designoftheagentforaspeciﬁcmutationorsetofmutations
(mRNA repair). The challenge to successfully build an eﬃ-
cacious PTGS agent has many pitfalls. This becomes greatly
compounded when the design has to be repeated many times
for a given disease gene, for example for those mutations
where a strong MD strategy might possibly be feasible.
The design and testing of a single PTGS agent requires
extensive time, eﬀort, and great expense when extending the
development through the preclinical animal testing phase.
And even if some such MD agents could be achieved, they
likelywouldhavevaryingeﬃcacytotreatdiﬀerentmutations
in a given gene. Yet, the development of such agents as
drugs for orphan genetic diseases is clearly indicated for
those suﬀering globally with such diseases. This need must
ultimately be balanced by the fact that many human disease
genes have substantial allelic heterogeneity or mutational
diversity. Mutation frequency can vary from common with
foundereﬀects(e.g.,P23HinhumanRHOgene)torare(e.g.,
K296M in rod rhodopsin, [182]), where only a single family
pedigree with two aﬀected individuals has been identiﬁed
globally to date. It is diﬃcult to anticipate that rare genetic
mutations would be targeted by a unique therapy that moves
up through clinical approval and the many hundreds of
millions of dollars that are needed to realize an eﬀective
and safe new drug. Research and development costs for
PTGS gene therapy will be colossal if testing of many designs
is needed to achieve optimized MD constructs for each
mutant mRNA. Rather, what is rational to expect is that a
single PTGS therapy directed to a single human disease gene
might eventually come to fruition. While KD or MI PTGS
therapy embraces a critical aspect of such an approach (one
therapy for all/most dominant disease mutations in a single
gene) the potential limitation of haploinsuﬃciency is already
prompting development of combined therapeutic strategies.
3.3. Combined PTGS Therapeutic Strategies. Am a j o ra d v a n -
tage of the KD or MI strategy for autosomal dominant
retinal or eye diseases is that the best hhRz or other PTGS18 Journal of Ophthalmology
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Figure 7: Comparison of mutation independent and mutation dependent strategies to PTGS therapy. The schematic representation shows
two folded mRNAs, one in which a MD strategy is being used to attack discrete mutations which obligate the site of attack to regions that
are likely to be buried, and the other is an MI strategy, where the best (most accessible) NUH↓ (lavender) or RNAi cleavage site is sought for
use. This challenge applies to hhRz or RNAi type therapeutics.
agent can be sought to cleave the mutant (and WT) mRNA
at the most accessible site and that a single KD agent
can be used to cleave many or all mutations so long as
the binding or NUH↓ cleavage motifs are not aﬀected
by mutation (probability <0.008). The KD strategy avoids
repetitive and expensive R&D for each new mutant as per
the MD strategy. One KD agent could provide therapy
for all or most mutations in each disease allele. We, and
others, have developed KD hhRzs that cut full-length mutant
human rod opsin mRNA and could be used to target all
currently known opsin adRP mutations [128, 183–189].
Since the most optimal (accessible) cleavage site for the
WT (and mutant) mRNAs is sought for attack, the critical
limiting variable indevelopment of PTGSagents,targetRNA
structure, is immediately embraced by this strategy. The
single and substantial disadvantage of the KD strategy is that
bothmutantandWTmRNAsareexpectedtobeequivalently
cleaved by the PTGS agent. The cellular phenotypic outcome
of expected equivalent knockdown of both WT and mutant
mRNAs and proteins will depend critically upon the cell in
which the gene is expressed, the function of the protein,
and the resultant levels of expression induced by the MI
PTGS agent. Let us consider RHO as a target of KD PTGS.
Rod opsin is expressed in abundance in rod photoreceptors
and is the visual pigment that subserves human scotopic
vision. There is a plethora of biochemical, biophysical, cell
biological, and genetic data on rhodopsin from over four
decades of research. WT rod rhodopsin is expressed in great
excess in photoreceptors to the levels over 2×108 copies/cell.
Essentially, all of the apoprotein is traﬃcked to the outer
segment,whereover98%islocalizedtotopologicallyisolated
disk membranes and under 2% is localized in the plasma
membrane. The human rod photoreceptor has the capacity
to detect and respond to the absorption of single photons
of appropriate energy, in part due to an extremely low level
of electrophysiological noise in darkness and a high gain
biochemicalampliﬁcationpathwayinlight.Nevertheless,the
dynamic physiological range of a human rod photoreceptor
saturatesupon approximately 200 photon absorptions [190].
Therefore, there are 99.9999% spare rhodopsin receptors in
the rod photoreceptor to guarantee quantum catch when
photondensityisextremelylow(dimstarlight).Thereissub-
stantial evidence that the rod photoreceptor autoregulates
the amount of opsin that is expressed in order to maintain
a constant daily absorption of photons in a process called
photostasis [191]. Rhodopsin itself appears to be the sensor
thatdrivesthistranscriptionalregulationpathway.Inrodents
kept in dim light, the levels of opsin expression increase, and
the outer segment length increases with no apparent change
in diameter. In increasingly higher levels of light, the level
of opsin expression decreases proportionally, and the outer
segment shrinks in length. At suﬃciently high levels of light,
there is light damage and cell death. How much WT opsin is
necessary to maintain the vitality and ideally the function of
the rod photoreceptor? This is a systems biology question of
critical relevance to the KD PTGS approach to gene therapy
of opsin-based adRP. We do not yet know the fullanswer, but
studies have pointed to an understanding of gross limits on
the range of normal rod opsin expression that are needed to
maintain the structure and physiological vitality of the rod
photoreceptor. There is substantial evidence that rhodopsin
isinatleast 50%excessforlong-termstructuralmaintenance
and survival. A recessive human mutation, E249ter, causes
50% loss of WT rhodopsin but is phenotypically silent in the
carrier state [192–194]. The heterozygous rod opsin mouse
(50% rhodopsin/rod) is similar to human E249ter carriers in
thatveryslow,ifany,retinaldegenerationoccursover90–120
days [195–197]. With only 50% of normal WT rhodopsin
being present, the outer segment lengths have shrunk to
approximately 50% of their normal length while apparentlyJournal of Ophthalmology 19
maintainingtheirdiameters.Whenrhodopsinlevelsdecrease
to 25% of normal in rats exposed to moderate light intensity,
many rods maintain vitality with shorter outer segments, but
many rods also die [191]. One might, therefore, hypothesize
that a signiﬁcant reduction (between 50%–75%) of WT rod
rhodopsin (rod sensitivity reduction by −0.3 to −0.6log)
would not cause rapid retinal degeneration in mammals.
Eﬃcacious PTGS knockdown (knockout is unlikely) of 50%
of total opsin protein would leave 25% WT and 25%
mutant in adRP rods. With severe mutants (e.g., C187Y), the
beneﬁts of reducing toxic gain of function mutant protein
are expected to oﬀset partial loss of WT opsin. However, WT
opsin levels must be maintained at around 50% to permit
rod survival inmouse[195,196].WhentheE249termutation
is homozygous and no WT opsin is synthesized, aﬀected
patients have early onset autosomal recessive RP [192]. The
mouse opsin knockout has a rapid retinal degeneration.
Opsin expression is essential for stable elaboration of an
outer segment and the formation of the phototransduction
apparatus. A single WT allele slows degeneration in the
presence of a single mutant opsin allele in mice [198]. This
suggeststhattheWTalleleisprotective,atleastundercertain
constraints. On the other hand there is a distinct limit on
overexpression of the WT opsin protein. Tan et al. [199]
showed in murine transgenic models that overexpression of
WTrodopsininrodphotoreceptorsbeyond125%ofnormal
levels promotes retinal degeneration. Thus, it would appear
that the tolerable limits of under and overexpression of WT
rod opsin in the mammalian rod photoreceptor likely range
from between 25% and 125%. This broad range indicates
that the photoreceptor as a system is highly tolerant or
capable of major ﬂuctuations of one of its critical functional
proteins. Many other phototransduction, structural, and
metabolic proteins are expected to shift their expression
levels in concert with opsin, as they are cotranscriptionally
regulated. This may have substantial functional implications
for cellular adaptations such as photostasis. If WT rhodopsin
levels at 25% and above exceed a threshold supportive of
rod photoreceptor vitality with an outer segment, then a
relatively eﬃcacious PTGS agent that knocks down 50% of
total opsin protein (WT and mutant) would be expected to
permit rod photoreceptor survival if the WT fraction was the
only component for consideration. However, the impact of
themutantproteincouldbeatoxicgainoffunctionmodality
for the cell. The level of knockdown of the mutant fraction
that is necessary to support vitality of the rod photoreceptor
will likely prove to be dependent upon the nature of the
mutation and the levels of photoreceptor systems biology
that are impacted by any gain of function toxicity. At present,
we can only anticipate that knockdown of mutant and WT
protein levels will vary depending upon the PTGS agent
that is used and its expression level in the appropriate cell
type. It is prudent to expect that there will be a dynamic
range of potential therapeutic outcomes from a single PTGS
agent in a given cellular system. Any therapeutic rationale
must embrace the intrinsic dynamic range of WT protein
expression, varying toxicity of the mutant protein, varying
therapeutic eﬃcacy of the PTGS agent itself, and a means of
transcriptionally regulating the PTGS agent both to tune the
therapeutic eﬀects or modulate against potential deleterious
eﬀects. These issues which tap into retinal systems biology
make PTGS therapy a diﬃcult but likely attainable goal in
the road ahead.
3.3.1. Combined Knockdown: Reconstitution Therapy. The
combined knockdown: reconstitution therapy (CKDRT)
embraces both the knockdown potential of the PTGS agent
and the protective eﬀect of the WT allele. In CKDRT,
both the native WT mRNA and the mutant mRNA are
targeted for therapeutic KD PTGS attack, but the WT mRNA
levels are reconstituted through expression of an engineered
allele that transcribes a WT mRNA that is resistant or
hardened to cleavage. Montgomery and Dietz [200]ﬁ r s t
reported that KD hhRzs embedded in an antisense sequence
were able to eﬃciently cleave ﬁbrillin-1 mRNA (disease
gene in ad Marfan’s syndrome). They suggested a general
approach in treating a variety of ad genetic diseases by
a knockdown hhRz/AS to suppress both mutant and WT
mRNAs in association with a WT reconstitution construct,
altered with respect to codon degeneracy, to reconstitute WT
expression to appropriate levels in order to prevent intrinsic
or therapeutic haploinsuﬃciency. It is this strategy that we
call CKDRT. Later in the same year, Millington-Ward et al.
[183] reported that ribozymes against opsin and peripherin
mRNAs could potentially be used in a CKDRT strategy as a
generalapproachfortherapiesofadgeneticdiseases.CKDRT
has also been applied to ad α-1 antitrypsin deﬁciency of
liver [201, 202]. There is increasing utility of the CKDRT
approachcombinedwithadecreasedfrequencyofreportson
design of MD PTGS agents [128, 183–185, 187, 188, 203–
206]. This is predictable given the severe constraints of
the MD approach as presented above. Nevertheless, while
CKDRT may be a suitable approach to clinical gene therapy,
for an autosomal dominant disease, there remains many
signiﬁcant scientiﬁc hurdles to be overcome, some of which
we will present here. The ﬁrst goal beyond development of
ap o t e n tK Do rM IP T G Sa g e n ti st oa c h i e v eaf u n c t i o n a l
allelic variant WT (aWT) mRNA with full potential to
translate suﬃcient levels of WT protein given normal levels
of transcription.
3.3.2. Design of Allelic Variant WT Expression Constructs. A
critical component of the CKDRT approach is that an aWT
variant of the WT gene or cDNA must be engineered to
express a processed mRNA that is resistant or hardened to
cleavage by the speciﬁc KD or MI PTGS agent. We consider
how target mRNA resistance can be engineered when the
PTGS strategies use hhRz or shRNA modalities. The design
of a cleavage-resistant mRNA for reconstituting WT protein
expression can be simple or complex, depending upon the
location and nature of the cleavage site in the mRNA relative
to the reading frame of the protein. We will ﬁrst consider
the development of an hhRz resistant aWT variant for
three attack sites in a given mRNA to indicate the potential
complexities in aWT variant design. We will use the rod
opsin (RHO) mRNA as a model in part, because there is a
crystal structure available for the WT rhodopsin protein that20 Journal of Ophthalmology
Table 3: Construction of allelic variant genes for combined knockdown reconstitute therapies.
Allelic variants for HhRz Therapeutics
5  UT Target Site
5  ...CCUGAGUGGCUGAGCUC↓AGGCCUU... (5  UT target site CUC↓)
5  ...CCUGAGUGGCUGAGCUG AGGCCUU... (aWT variant mRNA, CUG
cannot be cleaved)
Coding V230 region
5  ...CUC GUC UUC ACC GUC↓ AAG GAG GCC...3  (Coding region GUC↓)
L226 V227 F228 T229 V230 K231 E232 A233 (Amino acid triplets)
5  ...CUC GUC UUC ACC GUG AAG GAG GCC...3  (aWT variant mRNA,
L226 V227 F228 T229 V230 K231 E232 A233 GUG cannot be cleaved)
Single letter amino acid codes are used.
Coding F293 region
5  ...AUC CCA GCG UU↓C UUU GCC AAG AGC...3  (Coding region GUU↓)
I290 P291 A292 F293 F294 A295 K296 S297
GUU↓ cleavage site occurs within the F293 codon rather than cutting at the end of a codon.
5  ...AUC CCA GCG UGC UUU GCC AAG AGC...3  (aF293C variant mRNA)
I290 P291 A292 C293 F294 A295 K296 S297
It is unclear whether or not the F293C mutation is an allelic variant WT or has a protein phenotype.
Allelic variant for RNAi therapeutics in F293 region
5  ...AUC CCA GCG UUC UUU GCC AAG AGC...3  (Coding region RNAi site)
I290 P291 A292 F293 F294 A295 K296 S297
5  ...AUA CCC GCA UUU UUC GCG AAA AGG...3  (aWT variant mRNA)
I290 P291 A292 F293 F294 A295 K296 S297
aWT variant generated by codon degeneracy across the region of designed RNAi antisense annealing.
isencodedbythismRNA[207].Theproteincrystalstructure
can guide decision making in complex aWT variant gene
design, when the region of attack is in the protein-coding
region and the cleavage site occurs within rather than at
the end of a discrete codon. Consideration of WT protein
structure is essential to maintain the WT structure/function
and phenotype within the cell in which the aWT construct
would be expressed, especially in the speciﬁc case when
the aWT construct cannot be made silently with respect to
the protein reading frame. We will assume three sites for
hhRz attack with one in the 5 UT and the remaining two
in the coding region of the mRNA (Table 3) .L e tu sf u r t h e r
assume that these three sites have equivalent and high levels
of accessibility such that they would be sensible regions for
PTGS attack by a KD, MI hhRzs, or shRNAs. The 5 UT
and 3 UT regions of the processed mRNA are the easiest
regions for design of a aWT construct because maintaining
appropriate amino acid protein coding is not a variable.
aWT Construct Design for hhRz PTGS Agents. For a CUC↓
hhRz attack site in the 5 UT, it is relatively simple to
obviate the proven eﬃcacious hhRz cleavage at this site by
a single nt change from CUC↓ to CUG (Table 3). An hhRz
cleavage site is NUH↓ where N is any nt and H is any nt
except G. CUG is representative of any NUG site (GUG,
CUG, AUG, and UUG) that cannot be cleaved by a hhRz.
Hence, any chosen NUH↓ site in an accessible region of
the 5 UT (or 3 UT) could be converted to an NUG site
which cannot be cleaved to generate an aWT construct. If
the hhRz targeting this CUC↓ site has been shown to exert
all of its KD on the basis of RNA catalysis, with the loss of
all KD occurring through catalytic enzyme core mutations,
then this simple mutation creates a suﬃcient aWT construct.
One also wants to avoid the potential impact of signiﬁcant
antisense eﬀects of the chosen PTGS hhRz agent on the
aWT mRNA. Next, we consider two hypothetical accessible
hhRz cleavage sites in the coding region of the opsin mRNA.Journal of Ophthalmology 21
WT
(a)
V230V
(b)
Figure 8: Allelic variant human opsin construct. The hhRz cleavage site at V230 (GUC↓) was mutated by site-speciﬁc mutagenesis to the
degenerate human valine codon GUG. The V230V human opsin cDNA in a CMV expression vector (pCDNA3) was expressed in HEK293S
cells along with control human WT opsin CMV expression vector. Immunocytochemistry with 1D4 opsin monoclonal and an FITC-labeled
secondary antibody was conducted. Abundant human WT opsin expression and cell surface traﬃcking was noted in cells expressing WT (a)
or V230V aWT proteins (b).
WT (F293)
F293
(a)
F293C
F293C
(b)
Figure 9: Crystal structure analysis of allelic variant constructs. We analyzed the location of the F293C mutation in the bovine rod opsin
crystal structure (1F88.pdb). WT protein (a). The image shows the cutout region around the protonated Schiﬀ base linkage of 11-cis-retinal
(orange)toK296(bluesidechain).F293islavenderincolor.ThedisulﬁdebondbetweenC110andC187isinyellow.F293iswithin5 ˚ Aofthe
Schiﬀ base and within 10 ˚ A of the disulﬁde bond. F293C Mutation (b). The C293 sidechain is lavender in color with a yellow tip indicating
a free sulfhydryl group (-SH). The SH group is within 5 ˚ A of the Schiﬀ base and 10 ˚ A of the disulﬁde bond.
First, let us consider the site at V230 which is encoded by
aG U C ↓ triplet. In vitro hhRzs were designed that were
able to cleave at this site in the human RHO mRNA [185].
A single nt transversion leads to a GUG triplet which is
no longer cleavable by the targeting hhRz. Moreover, GUG
s t i l lc o d e sf o rV 2 3 0d u et od e g e n e r a c y .In vitro hhRzs
that successfully cleaved targets containing the GUC↓ site
failed to cleave the aWT variant RNA containing the GUG
triplet [185]. We engineered an aWT V230V (GUG) variant
cDNA by site-speciﬁc mutagenesis and put this construct
under the control of a strong CMV promoter in a cellular
expression plasmid. When we expressed this aWT V230V
(GUG) cDNA in HEK293S cells, we found, qualitatively, that
the expression and cellular distribution of WT protein was
not diﬀerent from otherwise equivalent V230 GUC↓ WT
expression construct by immunocytochemistry (Figure 8).
Assuming that a hhRz exerts full catalysis at this site without
substantialpureASeﬀects,anaWTwithpotentialforsuccess
has then been designed. Design of an aWT construct at the
second coding site (F93) demonstrates the complexity that
canarise,however,becauseanNUH↓cleavagesitewithinthe
codingregionmaynotobeytheserialorderofproteincoding
triplets but rather overlap them. The assumed accessible
targeted triplet GUU↓ overlaps two codons of human RHO
mRNA at A292 and F293 (Table 3). To make an aWT mRNA
that is resistant to hhRz attack the conversion of GUU↓
to noncleavable GUG results in a F293C (phenylalanine to
cysteine) mutation in the opsin polypeptide. Moreover, the22 Journal of Ophthalmology
location of this mutation at the protein level is one helical
turn away from the side chain of K296, which is the site of
covalentattachmentof11-cis-retinaltotheopsinapoprotein.
The replacement of a phenylalanine with a cysteine side
chain in such a critical location in the protein as an aWT
construct must be seriously considered. It is unclear whether
the mutation represents an identiﬁed allelic variant WT or
whether it is truly a mutation with a potential phenotypic
eﬀect on protein folding, function, or even potential toxicity
(gain of function). The impact of such a mutation may
be appreciated at a structural biological level if there is an
available crystal structure. Also, expression of the mutant
and normal proteins will be needed to compare functional
proﬁles, if adequate assays are available (e.g. [208, 209]).
A cellular expression to test for cell localization of the
mutant versus WT protein clearly is indicated to insure
that the variant protein has appropriate WT traﬃcking
phenotype. Tests for expressed mutant protein structure-
function relative to the native WT protein are also needed.
An opsin F293C mutation replaces a hydrophobic aromatic
ring sidechain with a polar and potentially reactive linear
sidechain. The location of the normal and mutant sidechains
in the rhodopsin crystal structure is shown (Figure 9).
While the length of the mutant sidechain is similar to
the native phenylalanine sidechain, the potentially reactive
cysteine sulfhydryl group is approximately 4 ˚ A from the
Schiﬀ base of K296 and 9 ˚ A from the C187 or C110
sidechains. A cysteine sidechain residue in this position
couldalterthelocalenvironmentimportantfor11-cis-retinal
docking and covalent ligation, or it could impair or intrude
upon disulﬁde bond formation between C110 and C187,
which is essential to the tertiary structure of rhodopsin
[210]. We found no biochemical structure function studies
in rhodopsin that reported on mutations at F293, so it is
unknown how well they might be tolerated, and coincident
biochemical or biophysical structure function studies at the
protein level could be important to assure that the allelic
variant protein indeed has WT characteristics. While such
a mutant protein that behaves like WT may be useful as an
aWT variant, rigorous experimental proof will be necessary
whenever development of an hhRz resistant mRNA requires
the development of such a potential aWT variant. Clearly,
if equivalently accessible regions present NUH↓ sites for
targeting, where it would be easier to construct an aWT
variant, it is prudent to consider further development of
CKDRT PTGS agents for such sites.
aWT Construct Design for RNAi PTGS Agents. The manner
in which an aWT- or RNAi-resistant target needs to be
designed is based strictly upon codon degeneracy within
the coding region of the protein, with little apparent
restriction elsewhere in the 5 UT and 3 UT regions, except
for otherwise unknown protein-binding regions that might
only be discovered empirically. For an aWT construct to be
built for resistance of the mRNA to annealing and cleavage
of charged RISC within the coding region of the protein,
it is necessary to exploit codon degeneracy to preserve
the amino acid sequence while substantially perturbing the
binding energy of the RISC to the target. Ideally, one will
want to preserve, to the best extent possible, the use of
the human codon bias (or animal codon bias in proof-
of-principle studies) in the selection of alternative coding
triplets, whenever these present so as not to potentially
impact WT protein expression levels. We demonstrate an
example of such a design (Table 3). As for the design of an
aWTvariantforhhRzresistance,itisnecessarytoempirically
test for resistance to knockdown of the aWT expression
construct mRNA in cultured cells relative to the original
WTexpressionconstruct.TheRISCcomplexoftheantisense
strand can tolerate several mismatches at the 5  and 3  ends
andstillbecapableofcleavage[75].While theenergeticrules
ofnearestneighborRNA:RNAbindingoftheguidesequence
within RISC to a potential target are not yet well established,
itisprobablyworthwhiletousenearestneighborcalculations
to minimize the binding energy of the charged RISC to the
aWT mRNA while preserving amino acid coding.
4. Conclusions and Outlook
The development of a successful PTGS agent for therapy is
one of the more diﬃcult tasks in molecular medicine today
and is a task that is well described by the term biocomplexity.
This biocomplexity is underscored by the fact that currently
there is only a single PTGS agent that is FDA-approved
for human use despite decades of academic and corporate
research. Here, we have presented an overview of currently
used PTGS technologies, the critical biophysical variables
that impact eﬃcacy, and the strategies that may be used for
geneticornongeneticretinaldiseases,wherePTGSagentsare
likely to have future therapeutic impact. We anticipate that
ribozymes have substantially greater therapeutic potential
than RNAi, because they can likely be as potent, given a
predetermined accessible region in the target mRNA, yet
they are not as fraught with the promiscuous oﬀ-target
eﬀects and toxicity that continues to be demonstrated with
RNAi(shRNA,andsiRNA).Wehavepresentedanoverriding
strategy used in this lab for development of hhRzs as
therapeutic agents. We have tried to present not only a base
of knowledge to begin work along this path, but also a view
of the pitfalls so that other investigators may ﬁnd it easier to
proceed down these investigative paths in the interests of the
patients.
There are several remaining issues that limit wide-scale
development of RNA drugs [95]. First, one must have highly
reliable and eﬃcient tools to ﬁrst solve the severe problem
of identifying those rare regions of target accessibility for
annealing of PTGS agents. Work in this lab has focused
on this problem of target mRNA accessibility with the
development of several HTS bioinformatics and experimen-
tal approaches ([211, 212], Taggart et al., in preparation).
Work must be directed to eﬃcient methods of searching for
these rare sites when the target is presented in biologically
complex mixtures such as the cell cytoplasm. Second, once
such accessible regions are determined there will likely be
a substantial number of PTGS agents that will need to be
tested for cellular eﬃcacy and toxicity. HTS approaches toJournal of Ophthalmology 23
screeningforcellularknockdownandtoxicitybyRzsorother
PTGS agents are needed to be able to quantitatively assess
and rank order both eﬃcacy and toxicity of sets of PTGS
agents targeting given accessible regions (Yau and Sullivan,
submitted; Kolniak and Sullivan, 2011; Butler et al., in
preparation [213–215]). Third, without colocalization with
targetmRNA,anyPTGSagentwillfailateﬃcacy.Bettertools
to rapidly identify cellular target RNA traﬃcking routes,
destination zip codes, and the sequence or structural motifs
that eﬀect such localization are needed. The later motifs
could then be integrated into the PTGS agent constructs as
complex chimeric RNAs with therapeutic, protective, and
traﬃcking domains. Fourth, while it is generally accepted
that Rz kinetic performance in vivo against native structure
target RNAs is 100–1000 fold less eﬀective than in vitro when
measured against short unstructured model substrates, it
has been diﬃcult to evaluate the robust kinetic performance
of ribozymes in mammalian cells. Approaches must be
developed to determine the kinetic performance and rate
limiting step(s) of a given PTGS agent in vivo,w h i c hi s
paramount to rational improvements for higher eﬃcacy, and
to understand the factors that inﬂuence intracellular failures
of PTGS agents. Recent development of similar approaches
in yeast might be beneﬁcial to guide the way for kinetic Rz
analysisinmammaliancells[216].Theengineeringofinvivo
cellular reporter systems for both the target mRNA and the
PTGS agent might also be useful (Yau and Sullivan, submit-
ted). Fifth, HTS assays to quantitatively assess the cellular
levels of target mRNA and protein which will need to move
beyond the classical gel-based approaches which are slow,
complex, and semiquantitative and have high variability. We
have developed a quantitative robotic imaging platform that
is able to measure target proteins and mRNA in transfected
cells that are ﬁxed and permeabilized in 96-well format
[213, 215] Butler et al., in preparation. Sixth, the power
of macromolecular RNA as a drug must embrace rational
and computational design for structure/activity assessments.
Computational and biophysical approaches to this problem
are emerging but will still currently require a fairly compact
therapeutic RNA design to utilize such tools. Seventh, and
ﬁnally, more eﬃcient means of preclinical analysis of PTGS
agents in appropriate animal models of disease are needed.
Intraocular injections and certainly subretinal injections are
complex multivariable surgical procedures when done on
human eyes, let alone small mouse eyes [217]. Assessing the
actual area of transduction as a normalization parameter to
either histological or electrophysiological assays of rescue is
paramount. In addition, for RNA drugs with potential to
translate to the human condition, the target mRNA that
drives the disease process in the animal models should be a
full-length human mRNA that recapitulates both the target
and the disease that will exist in future human clinical trials.
Even though the primary sequence may be homologous
over regions of PTGS targeting among mammalian cognate
mRNA targets, it is the secondary and tertiary structure
of the mRNA that governs accessibility and hence eﬃcacy
[212]. With human copies of the target mRNA in the
animal model, there is more conﬁdence that preclinical
eﬃcacy has hope of similar human clinical translation.
Currently, such animal models are rare [218]. This lab
remains dedicated to the resolution of bottlenecks in RNA
drug discovery and development of tools that will hasten
the pace of development of eﬃcacious and safe PTGS agents
as candidate therapeutics for human retinal and macular
degenerative diseases.
5.MaterialsandMethods
5.1. RNA Secondary Structure Prediction. The secondary
structure of full length RHO and BEST-1 mRNAs were
subjected to analysis, using free energy minimization (RNA-
Fold, MFold algorithm) [113], a Boltzmann-weighted sam-
pling of all substructures (SFold algorithm) (not shown)
[219–221], and local free energy analysis by OligoWalk [222]
(notshown).RNA-foldwasusedwithdefaultstoobtainMFE
structures of the larger RNAs for Figure 5. MFold was used
at 37◦C with 10kCal/mol window, for a maximum of 99
structures, and with a diﬀerence window of 3bp. OligoWalk
used the MFold output to obtain a LFE map along the
mRNAs. A window of 15nt, corresponding to symmetric
7/7nthhRz, was used to calculate the local free energy to
break the target mRNA. Regions of low LFE (less negative
or positive ΔG) indicate regions of low secondary structure
or dynamic ﬂuctuations.
5.2. Molecular Graphics. The bovine rod rhodopsin crystal
structure (1F88.pdb) was visualized and annotated with
ViewerPro (vers. 4.2) software (Accelrys). Changes in amino
acid sidechains were made with the same software. There
was no eﬀort to minimize the energy around the local site
of amino acid mutation (F293C) so the location of the
sidechain is approximate.
5.3. Site Speciﬁc Mutagenesis, Stable Opsin Cell Line Gen-
eration, and Immunocytochemistry. These approaches and
methods have been described in detail elsewhere [209].
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